<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1303257069
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2003
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        ZIAGEN 300MG TAB
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        ABACAVIR
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        300
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        60
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        944.75
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Delpharm Poznan " />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Delpharm Poznan 
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 354]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SAUDI INTERNATIONAL TRADING COMPANY LTD (SITCO)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Glaxo Saudi Arabia Ltd
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J05AF06
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>ZIAGEN is used to treat HIV (human immunodeficiency virus) infection in adults and in children.</strong></p><p>ZIAGEN contains the active ingredient abacavir sulfate. This belongs to a group of anti-retroviral medicines called <em>nucleoside analogue reverse transcriptase inhibitors (NRTIs)</em>, which are used to treat HIV infection.</p><p>ZIAGEN does not cure HIV infection; it reduces the amount of virus in your body, and keeps it at a low level. It also increases the CD4 cell count in your blood. CD4 cells are a type of white blood cells that are important in helping your body to fight infection.</p><p>Not everyone responds to treatment with ZIAGEN in the same way. Your doctor will monitor the effectiveness of your treatment.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Don&rsquo;t take ZIAGEN</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:13.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman",serif;mso-ascii-theme-font:major-bidi;
mso-fareast-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-theme-font:major-bidi;mso-ansi-language:EN-GB'><span style='mso-element:
field-begin'></span> DOCVARIABLE vault_nd_3278338c-25e9-4801-9f0f-24630bbeb347
\* MERGEFORMAT <span style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:13.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman",serif;mso-ascii-theme-font:major-bidi;
mso-fareast-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-theme-font:major-bidi;mso-ansi-language:EN-GB'><span style='mso-element:
field-end'></span></span></b><![endif]--></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are <strong>allergic</strong> (hypersensitive) to abacavir (or any other medicine containing abacavir &mdash; <strong>Kivexa, Trizivir or Triumeq</strong>), or any other ingredients of ZIAGEN (listed in <strong>Section 6</strong>)</p><p><strong>Carefully read all the information about hypersensitivity reactions in Section 4.</strong></p><p>If you think this applies to you,<strong> don&rsquo;t take ZIAGEN</strong> until you have checked with your doctor.</p><p><strong>Take special care with ZIAGEN</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:13.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman",serif;mso-ascii-theme-font:major-bidi;
mso-fareast-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-theme-font:major-bidi;mso-ansi-language:EN-GB'><span style='mso-element:
field-begin'></span> DOCVARIABLE vault_nd_3046a3d7-a799-4675-bb69-f22144ed1d0b
\* MERGEFORMAT <span style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:13.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman",serif;mso-ascii-theme-font:major-bidi;
mso-fareast-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-theme-font:major-bidi;mso-ansi-language:EN-GB'><span style='mso-element:
field-end'></span></span></b><![endif]--></p><p>Before you take ZIAGEN your doctor needs to know:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have ever had <strong>liver disease,</strong> including hepatitis B or C&nbsp;</p><p><strong>Talk to your doctor if any of these apply to you</strong>. You may need extra check-ups, including blood tests, while you&rsquo;re taking your medication. <strong>See Section 4 for more information</strong>.</p><p><strong>Conditions you need to look out for </strong></p><p>ZIAGEN can cause serious side effects.&nbsp; You must look out for certain symptoms while you are taking ZIAGEN, to reduce the risk of any problems.&nbsp;</p><p><strong>Hypersensitivity reactions</strong></p><p>ZIAGEN contains abacavir. Abacavir can cause a serious allergic reaction known as a hypersensitivity reaction, which can be life-threatening if treatment with abacavir containing products is not stopped.</p><p><strong>Carefully read all the information about hypersensitivity reactions in Section 4 of this leaflet.</strong></p><p><strong>Heart Disease</strong></p><p>Some studies have shown a small increase in the risk of having a heart attack in people taking abacavir, one of the active substances in ZIAGEN. Other studies have not shown any increased risk of heart attack in patients using abacavir</p><p><strong>Tell your doctor </strong>if you have heart problems, if you smoke, or have other illnesses that may increase your risk of heart disease such as high blood pressure, or diabetes. Don&rsquo;t stop taking ZIAGEN unless your doctor advises you to do so.</p><p><strong>Old infections flaring up</strong></p><p>See &lsquo;<em>Conditions you need to look out for</em><em>&rsquo; </em>in <strong>Section 4</strong><em>.</em></p><p><strong>Lactic acidosis</strong></p><p>A condition that is caused by build-up of lactic acid in the body.&nbsp; It is more likely to develop in people who have liver disease, especially in women.</p><p>See &lsquo;<em>Conditions you need to look out for</em><em>&rsquo; </em>in Section 4<em>.</em></p><p><strong>Other medicines and ZIAGEN</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:13.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman",serif;mso-ascii-theme-font:major-bidi;
mso-fareast-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-theme-font:major-bidi;mso-ansi-language:EN-GB'><span style='mso-element:
field-begin'></span> DOCVARIABLE vault_nd_90e72c01-cc8b-48f6-b4bc-dc9f8b1dd62b
\* MERGEFORMAT <span style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:13.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman",serif;mso-ascii-theme-font:major-bidi;
mso-fareast-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-theme-font:major-bidi;mso-ansi-language:EN-GB'><span style='mso-element:
field-end'></span></span></b><![endif]--></p><p><strong>Tell your doctor or pharmacist if you&#39;re taking any other medicines</strong>, if you&rsquo;ve taken any recently, or if you start taking new ones. This includes medicines bought without a prescription.</p><p><strong>Methadone and </strong><strong>ZIAGEN</strong></p><p>If you are taking methadone, your doctor may need to adjust your methadone dose, as abacavir (the active substance in ZIAGEN) increases the rate at which methadone leaves your body. This is unlikely to affect most methadone users.</p><p><strong>Riociguat and ZIAGEN</strong></p><p>If you are taking riociguat (a medicine used to treat high blood pressure in the</p><p>blood vessels (the pulmonary arteries) that carry blood from the heart to the lungs) your doctor may need to reduce your riociguat dose, as abacavir (the active substance in ZIAGEN) may increase riociguat blood levels.&nbsp;</p><p><strong>Pregnancy</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:13.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman",serif;mso-ascii-theme-font:major-bidi;
mso-fareast-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-theme-font:major-bidi;mso-ansi-language:EN-GB'><span style='mso-element:
field-begin'></span> DOCVARIABLE vault_nd_e1cad4e3-2c3b-41ec-853e-5b790bf0733b
\* MERGEFORMAT <span style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:13.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman",serif;mso-ascii-theme-font:major-bidi;
mso-fareast-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-theme-font:major-bidi;mso-ansi-language:EN-GB'><span style='mso-element:
field-end'></span></span></b><![endif]--></p><p>If you are<strong> pregnant</strong>, or <strong>think you could be, </strong>or if you are <strong>planning to become pregnant</strong>, <strong>don&rsquo;t take ZIAGEN</strong> without checking with your doctor. <strong>&nbsp;Your doctor </strong>will weigh up the benefit to you against the risk to your baby of taking ZIAGEN while you&#39;re pregnant.</p><p>In babies and infants exposed to NRTIs during pregnancy or labour small temporary increases in blood levels of a substance called lactate have been observed. Additionally, there have been very rare reports of diseases that affect the nervous system such as a delayed development and seizures. Overall, in children whose mothers took NRTIs during pregnancy, the benefit from the reduced chance of being infected with HIV is likely to be greater than the risk of suffering from side effects.</p><p><strong>Breast-feeding</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:13.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman",serif;mso-ascii-theme-font:major-bidi;
mso-fareast-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-theme-font:major-bidi;mso-ansi-language:EN-GB'><span style='mso-element:
field-begin'></span> DOCVARIABLE vault_nd_1563053e-26b2-48de-acc2-0e08ab31776d
\* MERGEFORMAT <span style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:13.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman",serif;mso-ascii-theme-font:major-bidi;
mso-fareast-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-theme-font:major-bidi;mso-ansi-language:EN-GB'><span style='mso-element:
field-end'></span></span></b><![endif]--></p><p><strong>Where possible, women who are HIV-positive should not breast-feed</strong>. This is because HIV infection can be passed on to the baby in breast milk. If formula feeding is not possible, you should get advice from your doctor.</p><p>A small amount of the ingredients in ZIAGEN can also pass into your breastmilk.</p><p>&Uacute; <strong>Talk to your doctor immediately </strong>if you&rsquo;re breast-feeding, or thinking about breast-feeding.</p><p><strong>While you&rsquo;re taking </strong><strong>ZIAGEN</strong></p><p><strong>You will need regular blood tests</strong></p><p>For as long as you&rsquo;re taking ZIAGEN, your doctor will arrange regular blood tests to check for side effects. There&rsquo;s more information about these side effects in <strong>Section 4 </strong>of this leaflet.</p><p><strong>Stay in regular contact with your doctor</strong></p><p>ZIAGEN helps to control your condition. You need to keep taking it every day to stop your illness getting worse. You may still develop other infections and illnesses linked to HIV infection.</p><p>&Uacute; <strong>Keep in touch with your doctor, and don&rsquo;t stop taking </strong><strong>ZIAGEN</strong> without your doctor&rsquo;s advice.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Always take ZIAGEN exactly as your doctor has told you to.</strong> Check with your doctor or pharmacist if you&#39;re not sure.</p><p><strong>How much to take</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:13.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman",serif;mso-ascii-theme-font:major-bidi;
mso-fareast-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-theme-font:major-bidi;mso-ansi-language:EN-GB'><span style='mso-element:
field-begin'></span> DOCVARIABLE vault_nd_7778e6eb-fdcf-4f11-840b-8c6d78ea2a20
\* MERGEFORMAT <span style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:13.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman",serif;mso-ascii-theme-font:major-bidi;
mso-fareast-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-theme-font:major-bidi;mso-ansi-language:EN-GB'><span style='mso-element:
field-end'></span></span></b><![endif]--></p><p>The usual dose of ZIAGEN in adults and in children weighing at least 25 kg is 600&nbsp;mg a day. This can be taken as 300 mg (one tablet) twice a day, or 600 mg (two tablets) once a day, as advised by your doctor.</p><p>The usual dose of ZIAGEN in children weighing at least 20 kg and less than 25 kg is 450 mg a day. This can be taken as 150 mg (half a tablet) in the morning and 300 mg (one whole tablet) in the evening, or 450 mg (one and a half tablets) once a day as advised by your doctor.</p><p>The usual dose of ZIAGEN in children weighing at least 14 kg and less than 20 kg is 300 mg a day. This can be taken as 150 mg (half a tablet) twice a day, or 300 mg (one whole tablet) once a day, as advised by your doctor.</p><p>ZIAGEN is also available as an oral solution (20 mg/ml) and may be prescribed by your doctor if you need a lower dose than usual or if you cannot take tablets.</p><p><strong>How to take</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:13.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman",serif;mso-ascii-theme-font:major-bidi;
mso-fareast-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-theme-font:major-bidi;mso-ansi-language:EN-GB'><span style='mso-element:
field-begin'></span> DOCVARIABLE vault_nd_f78084a0-7409-46a5-a499-68d29499991d
\* MERGEFORMAT <span style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:13.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman",serif;mso-ascii-theme-font:major-bidi;
mso-fareast-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-theme-font:major-bidi;mso-ansi-language:EN-GB'><span style='mso-element:
field-end'></span></span></b><![endif]--></p><p>Always take ZIAGEN exactly as your doctor has told you, and take great care not to miss any doses if at all possible. You should check with your doctor or pharmacist if you are not sure.</p><p>If your doctor wants to reduce your dose of ZIAGEN, for example if you have liver problems, then you may be prescribed abacavir as the oral solution.</p><p><strong>If you forget to take ZIAGEN</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:13.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman",serif;mso-ascii-theme-font:major-bidi;
mso-fareast-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-theme-font:major-bidi;mso-ansi-language:EN-GB'><span style='mso-element:
field-begin'></span> DOCVARIABLE vault_nd_bd6177a6-1265-4c2b-a384-21f5de1fad0c
\* MERGEFORMAT <span style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:13.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman",serif;mso-ascii-theme-font:major-bidi;
mso-fareast-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-theme-font:major-bidi;mso-ansi-language:EN-GB'><span style='mso-element:
field-end'></span></span></b><![endif]--></p><p><strong>Don&#39;t take a double dose </strong>to make up for a missed dose. Just take it as soon as you remember.</p><p>If you are not sure what to do, ask your doctor or pharmacist.</p><p><strong>If you take too much ZIAGEN</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:13.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman",serif;mso-ascii-theme-font:major-bidi;
mso-fareast-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-theme-font:major-bidi;mso-ansi-language:EN-GB'><span style='mso-element:
field-begin'></span> DOCVARIABLE vault_nd_93e8ae01-854d-4a19-ac6d-019bbc911b9b
\* MERGEFORMAT <span style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:13.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman",serif;mso-ascii-theme-font:major-bidi;
mso-fareast-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-theme-font:major-bidi;mso-ansi-language:EN-GB'><span style='mso-element:
field-end'></span></span></b><![endif]--></p><p>If you take<em> </em>too many tablets or too much oral solution of ZIAGEN, <strong>contact your doctor or pharmacist, or your nearest hospital emergency department for advice.</strong> If possible, show them the ZIAGEN pack.</p><p><strong>Don&rsquo;t stop ZIAGEN without advice</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:13.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman",serif;mso-ascii-theme-font:major-bidi;
mso-fareast-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-theme-font:major-bidi;mso-ansi-language:EN-GB'><span style='mso-element:
field-begin'></span> DOCVARIABLE vault_nd_7e4e260f-0b42-40fe-b201-97463caeab7f
\* MERGEFORMAT <span style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:13.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman",serif;mso-ascii-theme-font:major-bidi;
mso-fareast-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-theme-font:major-bidi;mso-ansi-language:EN-GB'><span style='mso-element:
field-end'></span></span></b><![endif]--></p><p>If you have stopped taking ZIAGEN for any reason, particularly because you think you are having side effects or for other illness, it is important that you contact your doctor before restarting.&nbsp; In some cases, your doctor will ask you to restart ZIAGEN in a place where you will be able to get ready access to medical care if needed.</p><p>If you have hepatitis B infection, don&rsquo;t stop ZIAGEN without your doctor&rsquo;s advice, as your hepatitis may come back.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, ZIAGEN can cause side effects, although not everybody gets them.</p><p>When you&rsquo;re being treated for HIV, it can be hard to tell whether a symptom is a side effect of ZIAGEN or other medicines you are taking, or an effect of the HIV disease itself. <strong>So, it is very important to talk to your doctor about any changes in your health</strong>.</p><table border="1" cellspacing="1" cellpadding="1" style="width:800px"><tbody><tr><td><p>ZIAGEN can cause a serious allergic reaction known as a hypersensitivity reaction, see &lsquo;Hypersensitivity reactions&rsquo; in <em>&lsquo;Conditions you need to look out for&rsquo;</em> in <strong>Section 4</strong>.</p><p>It is very important that you read and understand the information about this serious reaction.</p></td></tr></tbody></table><p><strong>As well as the side effects listed below for </strong><strong>ZIAGEN</strong>, other conditions can develop during combination therapy for&nbsp;HIV.</p><p>It is important to read the information in <em>&lsquo;Conditions you need to look out for&rsquo;</em> in <strong>Section 4.</strong></p><p><strong>Conditions you need to look out for</strong></p><table border="1" cellspacing="1" cellpadding="1" style="width:800px"><tbody><tr><td><p><strong>Hypersensitivity reactions</strong></p><p><strong>ZIAGEN</strong> contains <strong>abacavir</strong> (which is also an active ingredient in <strong>Kivexa, Trizivir</strong> and <strong>Triumeq</strong>).</p><p>Abacavir can cause a serious allergic reaction known as a hypersensitivity reaction, which can be life-threatening if treatment with abacavir containing products is not stopped.</p><p><strong>Who gets these reactions?</strong></p><p>Anyone taking ZIAGEN could develop a hypersensitivity reaction, which could be life threatening if they continue to take ZIAGEN.</p><p>You are more likely to develop such a reaction if you have a gene called<strong> HLA-B*5701</strong> (but you can get a reaction even if you don&rsquo;t have this gene). If possible, you will have been tested for this gene before ZIAGEN was prescribed for you. <strong>If you know you have this gene, tell your doctor before you take </strong><strong>ZIAGEN</strong><strong>.</strong></p><p><strong>What are the symptoms?</strong></p><p>The most common symptoms are:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>fever</strong> (high temperature) and <strong>skin rash</strong>.</p><p>Other common symptoms are:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nausea (feeling sick), vomiting (being sick), diarrhoea, abdominal (stomach) pain, severe tiredness, shortness of breath, cough, headache, muscle pain and discomfort.</p><p>Other less common symptoms can include:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pains in the joints , swelling of the neck, serious breathing problems, sore throat</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; occasionally, inflammation of the eye<em> (conjunctivitis)</em>, mouth ulcers, low blood pressure, tingling or numbness of the hands or feet.</p><p><strong>When do these reactions happen?</strong></p><p>Hypersensitivity reactions can start at any time during treatment with ZIAGEN, but are more likely during the first 6 weeks of treatment.</p><p><strong>Contact your doctor immediately:</strong></p><p><strong>1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you get a skin rash, OR</strong></p><p><strong>2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you get symptoms from at least 2 of the following groups:</strong></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; - fever</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; - shortness of breath, sore throat or cough</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; - nausea or vomiting, diarrhoea or stomach pain</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; - severe tiredness or achiness, or generally feeling ill.</p><p>Your doctor may advise you to stop taking ZIAGEN</p><p><strong>Always carry your Alert Card while you are taking </strong><strong>ZIAGEN</strong><strong>.</strong></p><p><strong>If you have stopped taking </strong><strong>ZIAGEN</strong></p><p>If you have stopped taking ZIAGEN because of a hypersensitivity reaction, <strong>you must NEVER AGAIN take ZIAGEN, or any other medicine containing abacavir (Kivexa, Trizivir or Triumeq). </strong>If you do, within hours, your blood pressure could fall dangerously low which could result in death.</p><p>If you have stopped taking ZIAGEN for any reason &mdash; especially because you think you are having side effects, or because you have another illness:</p><p><strong>Talk to your doctor before you start again. </strong>Your doctor will check whether your symptoms were related to a hypersensitivity reaction. If the doctor thinks they may have been,<strong> you will then be told never again to take ZIAGEN, or any other medicine containing abacavir. </strong>It is important that you follow this advice.</p><p>Occasionally, reactions have developed in people who start taking abacavir again, and had only one symptom on the Alert Card before they stopped taking it.</p><p>Very rarely, reactions have developed in people who start taking abacavir again, but who had no symptoms before they stopped taking it.</p><p>If your doctor advises that you can start taking ZIAGEN again, you may be asked to take your first doses in a place where you will have ready access to medical care if you need it.</p><p>If you are hypersensitive to ZIAGEN, return all your unused ZIAGEN tablets for safe disposal. Ask your doctor or pharmacist for advice.</p><p>The ZIAGEN pack includes an <strong>Alert Card</strong>, to remind you and medical staff about hypersensitivity reactions. <strong>Detach this card and keep it with you at all times</strong>.</p></td></tr></tbody></table><p>Combination therapy such as ZIAGEN may cause other conditions to develop during HIV treatment.</p><p><strong>Old infections may flare up</strong></p><p>People with advanced HIV infection (AIDS) have weak immune systems, and are more likely to develop serious infections (opportunistic infections). When these people start treatment, they may find that old, hidden infections flare up, causing signs and symptoms of inflammation. These symptoms are probably caused by the body&rsquo;s immune system becoming stronger, so that the body starts to fight these infections.</p><p>If you get any symptoms of infection while you&rsquo;re taking ZIAGEN:</p><p><strong>Tell your doctor immediately</strong>. Don&rsquo;t take other medicines for the infection without your doctor&rsquo;s advice.</p><p><strong>Lactic acidosis is a rare but serious side effect</strong></p><p>Some people taking ZIAGEN, or other medicines like it (NRTIs), develop a condition called lactic acidosis, together with an enlarged liver.</p><p>Lactic acidosis is caused by a build-up of lactic acid in the body. It is rare; if it happens, it usually develops after a few months of treatment. It can be life-threatening, causing failure of internal organs.</p><p>Lactic acidosis is more likely to develop in people who have liver disease, especially in women.</p><p>Signs of lactic acidosis include:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; deep, rapid, difficult breathing</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; drowsiness</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; numbness or weakness in the limbs</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling sick (nausea), being sick (vomiting)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stomach pain.</p><p>During your treatment, your doctor will monitor you for signs of lactic acidosis. If you have any of the symptoms listed above or any other symptoms that worry you:</p><p>&Uacute; See your doctor as soon as possible.</p><p><strong>Common side effects</strong></p><p>These may affect <strong>up to 1 in 10 people:</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headache</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling sick (<em>nausea</em>)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hypersensitivity reaction (<em>see &lsquo;hypersensitivity reactions&rsquo; section above</em>)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; being sick (<em>vomiting</em>)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diarrhoea</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; loss of appetite</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tiredness, lack of energy</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; high temperature(<em>fever</em>)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin rash</p><p><strong>Rare side effects </strong></p><p>These may affect <strong>up to 1 in 1000</strong> <strong>people</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; lactic acidosis (see section<em>,</em> <em>&lsquo;Conditions you need to look out for&rsquo;</em>)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the pancreas (<em>pancreatitis</em>)</p><p><strong>Very rare side effects</strong></p><p>These may affect <strong>up to 1 in 10,000 people</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin rash, which may form blisters and looks like small targets (central dark spots surrounded by a paler area, with a dark ring around the edge)<em> (erythema multiforme)</em></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a widespread rash with blisters and peeling skin, particularly around the mouth, nose, eyes and genitals<em> (Stevens&ndash;Johnson syndrome)</em>, and a more severe form causing skin peeling in more than 30% of the body surface (toxic epidermal necrolysis).</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>If you notice any of these symptoms contact a doctor urgently.</p></td></tr></tbody></table><p><strong>Other effects may show up in blood tests</strong></p><p>Combination therapy for HIV can also cause:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp; increased levels of lactic acid in the blood, which on rare occasions can lead to lactic acidosis</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp; increased levels of sugar and fats (triglycerides and cholesterol) in the blood</p><p><strong>If you get side effects</strong></p><p>&Uacute; <strong>Tell your doctor or pharmacist</strong> if any of the side effects become<strong> severe or&nbsp;&nbsp;&nbsp;&nbsp; troublesome</strong>, or if you notice any side effects not listed in this leaflet.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep out of the reach and sight of children.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not take ZIAGEN after the expiry date shown on the pack or the bottle</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Store Ziagen below 30&deg;C.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Don&rsquo;t dispose of any unwanted ZIAGEN tablets or ZIAGEN oral solution in your wastewater or household rubbish.&nbsp; Ask your pharmacist how to dispose of medicines no longer required.&nbsp; This will help to protect the environment</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is abacavir sulfate.</p><p>Each film-coated tablet contains 300 mg abacavir sulfate.</p><p>The other ingredients are:</p><p><em>Tablet Core </em></p><p>Microcrystalline cellulose</p><p>Sodium starch glycollate</p><p>Magnesium stearate</p><p>Colloidal anhydrous silica.</p><p><em>&nbsp;</em></p><p><em>Tablet Coating </em></p><p>Triacetin</p><p>Methylhydroxypropylcellulose</p><p>Titanium dioxide</p><p>Polysorbate 80</p><p>Iron oxide yellow.</p><p>&nbsp;</p><table border="1" align="center" cellspacing="1" cellpadding="1" style="width:800px"><tbody><tr><td style="text-align:center"><p><strong>Alert Card</strong></p><table border="1" align="center" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td><p><strong>IMPORTANT ALERT CARD</strong></p><p><strong>ZIAGEN (abacavir sulfate) tablets or oral solution</strong></p><p><strong>Carry this card with you at all times</strong></p></td></tr></tbody></table><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="2" style="vertical-align:top"><p style="text-align:left">Patients taking ZIAGEN may develop a hypersensitivity reaction (serious allergic reaction)<strong> </strong>which <strong>can be life threatening </strong>if treatment with ZIAGEN is continued. <strong>CONTACT YOUR DOCTOR IMMEDIATELY for advice on whether you should stop taking ZIAGEN if:</strong></p></td></tr><tr><td style="vertical-align:top"><p style="text-align:left"><strong>you get a skin rash OR</strong></p></td><td><p style="text-align:left">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p style="text-align:left"><strong>you get one or more symptoms from at least TWO of the following groups</strong></p></td><td><p style="text-align:left">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p style="text-align:left"><strong>-&nbsp; </strong>fever</p></td><td><p style="text-align:left">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p style="text-align:left"><strong>-&nbsp; </strong>shortness of breath, sore throat or cough</p></td><td><p style="text-align:left">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p style="text-align:left"><strong>-&nbsp; </strong>nausea or vomiting or diarrhoea or abdominal pain</p></td><td><p style="text-align:left">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p style="text-align:left"><strong>-&nbsp; </strong>severe tiredness or achiness or generally ill feeling</p></td><td><p style="text-align:left">&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p style="text-align:left">If you have discontinued ZIAGEN due to this reaction, <strong>YOU MUST NEVER</strong> take ZIAGEN or any other medicine containing abacavir (<em>KIVEXA</em>, <em>TRIZIVIR or TRIUMEQ</em>) again, as <strong>within hours</strong> you may experience a life-threatening lowering of your blood pressure or death.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p style="text-align:left"><strong>CARTON PANEL</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p style="text-align:left">The following text must be included on one of the carton panels:</p></td></tr><tr><td style="vertical-align:top"><p style="text-align:left"><strong>Detach enclosed Alert Card, it contains important safety information.</strong></p></td><td><p style="text-align:left">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p style="text-align:left">WARNING! In case of any symptoms suggesting hypersensitivity reactions, contact your doctor IMMEDIATELY.</p></td><td><p style="text-align:left">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p style="text-align:left"><!--[if supportFields]><span
  style='font-size:12.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman",serif;
  mso-ascii-theme-font:major-bidi;mso-fareast-font-family:"Times New Roman";
  mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi;mso-ansi-language:
  EN-GB'><span style='mso-element:field-begin'></span>SYMBOL 8220\u</span><![endif]--><!--[if supportFields]><span
  style='font-size:12.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman",serif;
  mso-ascii-theme-font:major-bidi;mso-fareast-font-family:"Times New Roman";
  mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi;mso-ansi-language:
  EN-GB'><span style='mso-element:field-end'></span></span><![endif]--><strong>Pull here</strong><!--[if supportFields]><span
  style='font-size:12.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman",serif;
  mso-ascii-theme-font:major-bidi;mso-fareast-font-family:"Times New Roman";
  mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi;mso-ansi-language:
  EN-GB'><span style='mso-element:field-begin'></span>SYMBOL 8221\u</span><![endif]--><!--[if supportFields]><span
  style='font-size:12.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman",serif;
  mso-ascii-theme-font:major-bidi;mso-fareast-font-family:"Times New Roman";
  mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi;mso-ansi-language:
  EN-GB'><span style='mso-element:field-end'></span></span><![endif]--> (with Alert card attached).</p></td><td><p>&nbsp;</p></td></tr></tbody></table></td></tr></tbody></table><p style="text-align:center">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                The scored film coated tablets are yellow, capsule shaped and marked with GX 623 on both sides.

Not all presentations are available in every country.
ZIAGEN is trademark owned by or licensed to the ViiV Healthcare group of companies.
© 2023 ViiV Healthcare group of companies. All rights reserved.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Manufactured by: </strong></p><p>Delpharm Poznań Sp&oacute;łka Akcyjna, ul. Grunwaldzka 189, 60-322 Poznan, Poland</p><p><strong>Marketing Authorisation Holder: </strong></p><p>Glaxo Saudi Arabia Ltd.* Jeddah, KSA.</p><p>Address: P.O. Box 22617 Jeddah 21416 &ndash; Kingdom of Saudi Arabia.</p><p>*member of the GSK group of companies</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Version Number: GDS33 
Version Date: 20 June 2022
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL"><strong>يُستخدم زياجين في علاج عدوى فيروس نقص المناعة البشرية </strong><strong>(HIV)</strong><strong> لدى البالغين والأطفال.</strong><!--[if supportFields]><b><span
lang=EN-US style='font-size:12.0pt;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";mso-fareast-language:AR-SA'><span
style='mso-element:field-begin'></span></span></b><span dir=LTR></span><span
dir=LTR></span><b><span lang=EN-US dir=LTR style='font-size:12.0pt;font-family:
"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";mso-fareast-language:
AR-SA'><span dir=LTR></span><span dir=LTR></span> DOCVARIABLE
VAULT_ND_7b0f1752-9b8a-4122-a0de-d1a737b77a96 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
lang=EN-US style='font-size:12.0pt;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";mso-fareast-language:AR-SA'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p dir="RTL">يحتوي زياجين على المكوّن الفعَّال سلفات الأباكاﭬـير. ينتمي هذا المكون إلى فئة من الأدوية المضادة للفيروسات الرجعية تُسمى الأدوية النيوكليوزيدية المضادة لإنزيم المنتسخة المعاكس <em>(NRTI)</em>، والتي تُستخدم لعلاج العدوى بفيروس نقص المناعة البشرية.</p><p dir="RTL">إن زياجين لا يُشفي تمامًا من مرض نقص المناعة البشرية؛ وإنما يقلل من انتشار الفيروس في الجسم ويجعله في مستوى منخفض. كما يعمل على زيادة عدد خلايا CD4 (كتلة التمايز ٤) المناعية في الدم. وخلايا CD4 (كتلة التمايز ٤) هي نوع من خلايا الدم البيضاء التي لها دور مهم في مساعدة الجسم على مكافحة العدوى.</p><p dir="RTL">وتختلف استجابة المرضى للعلاج بعقار زياجين. سوف يراقب الطبيب مدى فعالية العلاج لديك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>تجنّب تناول زياجين في الحالات التالية</strong><!--[if supportFields]><b><span
lang=EN-US style='font-size:13.0pt;font-family:"Arial",sans-serif;mso-fareast-font-family:
Arial;mso-fareast-language:AR-SA'><span style='mso-element:field-begin'></span></span></b><span
dir=LTR></span><span dir=LTR></span><b><span lang=EN-US dir=LTR
style='font-size:13.0pt;font-family:"Arial",sans-serif;mso-fareast-font-family:
Arial;mso-fareast-language:AR-SA'><span dir=LTR></span><span dir=LTR></span>
DOCVARIABLE VAULT_ND_d610dbf7-bde6-4c9a-9a0e-d2fdb94b3d10 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
lang=EN-US style='font-size:13.0pt;font-family:"Arial",sans-serif;mso-fareast-font-family:
Arial;mso-fareast-language:AR-SA'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت لديك <strong>حساسية</strong> (فرط حساسية) لأباكاﭬـير (أو أي دواء آخر يحتوي على أباكاﭬـير - <strong>كيـﭭـيكسا أو تريزيـﭭـير أو ترايوميك</strong>) أو أي من مكوّنات زياجين (الواردة في <strong>القسم</strong> <strong>٦</strong>)</p><p dir="RTL"><strong>اقرأ بعناية جميع المعلومات المتعلقة بتفاعلات فرط الحساسية في القسم ٤.</strong><!--[if supportFields]><b><span lang=EN-US
style='font-size:12.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
"Times New Roman";mso-fareast-language:AR-SA'><span style='mso-element:field-begin'></span></span></b><span
dir=LTR></span><span dir=LTR></span><b><span lang=EN-US dir=LTR
style='font-size:12.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
"Times New Roman";mso-fareast-language:AR-SA'><span dir=LTR></span><span
dir=LTR></span> DOCVARIABLE VAULT_ND_e468d31f-2646-4640-8118-77bbc3730ecb \*
MERGEFORMAT <span style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
lang=EN-US style='font-size:12.0pt;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";mso-fareast-language:AR-SA'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">إذا رأيت أن هذه الحالات تنطبق عليك، <strong>امتنع عن تناول زياجين</strong> حتى تستشير طبيبك.</p><p dir="RTL"><strong>ينبغي توخي الحذر عند استخدام زياجين</strong></p><p dir="RTL">قبل تناول زياجين، يحتاج طبيبك إلى معرفة ما يلي:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا سبق لك، في أي وقت، الإصابة <strong>بأمراض بالكبد</strong>، بما في ذلك التهاب الكبد الوبائي بي أو سي</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>استشر طبيبك إذا كنت تعاني من أي من الأمراض سالفة الذكر</strong>. قد تحتاج إلى مزيد من الفحوصات، بما في ذلك فحوصات الدم، أثناء تناول العلاج. <strong>راجع القسم ٤ لمزيد من المعلومات.</strong></p><p dir="RTL"><strong>حالات ينبغي الانتباه لها</strong><!--[if supportFields]><b><span lang=AR-SA
style='font-size:12.0pt;font-family:"Times New Roman",serif;mso-ascii-font-family:
Arial;mso-fareast-font-family:"Times New Roman";mso-fareast-language:AR-SA'><span
style='mso-element:field-begin'></span> </span></b><b><span lang=EN-US dir=LTR
style='font-size:12.0pt;font-family:"Arial",sans-serif;mso-fareast-font-family:
"Times New Roman";mso-hansi-font-family:"Times New Roman";mso-bidi-font-family:
"Times New Roman";mso-fareast-language:AR-SA'>DOCVARIABLE</span></b><span
dir=RTL></span><span dir=RTL></span><b><span lang=EN-US style='font-size:12.0pt;
font-family:"Times New Roman",serif;mso-ascii-font-family:Arial;mso-fareast-font-family:
"Times New Roman";mso-fareast-language:AR-SA'><span dir=RTL></span><span
dir=RTL></span> </span></b><b><span lang=EN-US dir=LTR style='font-size:12.0pt;
font-family:"Arial",sans-serif;mso-fareast-font-family:"Times New Roman";
mso-hansi-font-family:"Times New Roman";mso-bidi-font-family:"Times New Roman";
mso-fareast-language:AR-SA'>VAULT_ND_203cefed-d7ee-4565-addd-34d70792d31f \*
MERGEFORMAT</span></b><span dir=RTL></span><span dir=RTL></span><b><span
lang=EN-US style='font-size:12.0pt;font-family:"Times New Roman",serif;
mso-ascii-font-family:Arial;mso-fareast-font-family:"Times New Roman";
mso-fareast-language:AR-SA'><span dir=RTL></span><span dir=RTL></span> </span></b><b><span
lang=AR-SA style='font-size:12.0pt;font-family:"Times New Roman",serif;
mso-ascii-font-family:Arial;mso-fareast-font-family:"Times New Roman";
mso-fareast-language:AR-SA'><span style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
lang=AR-SA style='font-size:12.0pt;font-family:"Times New Roman",serif;
mso-ascii-font-family:Arial;mso-fareast-font-family:"Times New Roman";
mso-fareast-language:AR-SA'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p dir="RTL">يمكن أن يتسبب زياجين في حدوث آثار جانبية خطيرة. لذا يتعين عليك الانتباه لبعض الأعراض المعينة أثناء تناول زياجين للحد من حدوث مشكلات.</p><p dir="RTL"><strong>تفاعلات فرط الحساسية</strong><!--[if supportFields]><b><span
lang=EN-US style='font-size:12.0pt;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";mso-fareast-language:AR-SA'><span
style='mso-element:field-begin'></span></span></b><span dir=LTR></span><span
dir=LTR></span><b><span lang=EN-US dir=LTR style='font-size:12.0pt;font-family:
"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";mso-fareast-language:
AR-SA'><span dir=LTR></span><span dir=LTR></span> DOCVARIABLE
VAULT_ND_af28c155-76cc-4cd7-93d2-f3dc77c30ff6 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
lang=EN-US style='font-size:12.0pt;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";mso-fareast-language:AR-SA'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p dir="RTL">يحتوي زياجين على أباكاﭬـير. وقد يسبب أباكاﭬـير تفاعلات حساسية خطيرة (تعرف باسم تفاعلات فرط الحساسية)، والتي يمكن أن تهدد حياة الشخص في حالة عدم التوقف عن العلاج باستخدام المنتجات التي تحتوي على أباكاﭬـير.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>اقرأ بعناية جميع المعلومات المتعلقة بتفاعلات فرط الحساسية في القسم ٤ من هذه النشرة.</strong><!--[if supportFields]><b><span
lang=EN-US style='font-size:12.0pt;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";mso-fareast-language:AR-SA'><span
style='mso-element:field-begin'></span></span></b><span dir=LTR></span><span
dir=LTR></span><b><span lang=EN-US dir=LTR style='font-size:12.0pt;font-family:
"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";mso-fareast-language:
AR-SA'><span dir=LTR></span><span dir=LTR></span> DOCVARIABLE
VAULT_ND_2fbce04d-8fed-4219-95c7-260977a92df9 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
lang=EN-US style='font-size:12.0pt;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";mso-fareast-language:AR-SA'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p dir="RTL"><strong>أمراض القلب</strong></p><p dir="RTL">أظهرت بعض الدراسات زيادة طفيفة في احتمال وقوع أزمة قلبية للمرضى الذين يتناولون أباكاﭬـير، وهو أحد المواد الفعالة في زياجين. بينما لم تظهر الدراسات الأخرى أي زيادة محتملة للإصابة بأزمة قلبية لدى المرضى الذين يستخدمون أباكاﭬـير.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أخبر الطبيب</strong> إذا كنت تعاني من مشكلات في القلب أو كنت تدخن أو تعاني من أي مرض آخر قد يزيد من احتمال الإصابة بأمراض القلب كارتفاع ضغط الدم أو البول السكري. لا تتوقف عن تناول زياجين ما لم ينصحك الطبيب بهذا.</p><p dir="RTL"><strong>نشاط الإصابات السابقة</strong><!--[if supportFields]><b><span
lang=EN-US style='font-size:12.0pt;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";mso-fareast-language:AR-SA'><span
style='mso-element:field-begin'></span></span></b><span dir=LTR></span><span
dir=LTR></span><b><span lang=EN-US dir=LTR style='font-size:12.0pt;font-family:
"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";mso-fareast-language:
AR-SA'><span dir=LTR></span><span dir=LTR></span> DOCVARIABLE
VAULT_ND_3cbf8a30-8198-4c39-b080-aef2bf7735e0 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
lang=EN-US style='font-size:12.0pt;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";mso-fareast-language:AR-SA'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p dir="RTL">راجع <em>&quot;حالات ينبغي الانتباه لها&quot;</em> في <strong>القسم</strong> <strong>٤</strong>.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحماض اللاكتيكي</strong></p><p dir="RTL">هي حالة طبية تحدث نتيجة تراكم حمض اللاكتيك في الجسم. ويشيع حدوثها لدى مرضى الكبد، وخاصة النساء منهم.</p><p dir="RTL">راجع &quot;<em>حالات ينبغي الانتباه لها</em>&quot; في القسم ٤.</p><p dir="RTL"><strong>الأدوية الأخرى وزياجين</strong><!--[if supportFields]><b><span
lang=EN-US style='font-size:13.0pt;font-family:"Arial",sans-serif;mso-fareast-font-family:
Arial;mso-fareast-language:AR-SA'><span style='mso-element:field-begin'></span></span></b><span
dir=LTR></span><span dir=LTR></span><b><span lang=EN-US dir=LTR
style='font-size:13.0pt;font-family:"Arial",sans-serif;mso-fareast-font-family:
Arial;mso-fareast-language:AR-SA'><span dir=LTR></span><span dir=LTR></span>
DOCVARIABLE VAULT_ND_c1495368-ad95-4367-a165-0c1020652332 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
lang=EN-US style='font-size:13.0pt;font-family:"Arial",sans-serif;mso-fareast-font-family:
Arial;mso-fareast-language:AR-SA'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p dir="RTL"><strong>قم بإبلاغ الطبيب أو الصيدلي إذا كنت تتناول أدوية أخرى في الوقت الحالي</strong>، أو تناولت بعض الأدوية مؤخرًا أو عند الشروع في تناول أدوية جديدة. ويشمل هذا الأدوية التي تُشترى دون وصفة طبية.</p><p dir="RTL"><strong>ميثادون وعقار زياجين</strong><!--[if supportFields]><b><span
lang=EN-US style='font-size:12.0pt;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";mso-fareast-language:AR-SA'><span
style='mso-element:field-begin'></span></span></b><span dir=LTR></span><span
dir=LTR></span><b><span lang=EN-US dir=LTR style='font-size:12.0pt;font-family:
"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";mso-fareast-language:
AR-SA'><span dir=LTR></span><span dir=LTR></span> DOCVARIABLE
VAULT_ND_0106296f-15cd-4d93-b3af-52b4d3bc0f7b \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
lang=EN-US style='font-size:12.0pt;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";mso-fareast-language:AR-SA'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p dir="RTL">إذا كنت تتناول عقار ميثادون، فقد يحتاج الطبيب إلى تعديل الجرعة التي تتناولها لأن أباكاﭬـير (المادة الفعالة في زياجين) يزيد من المعدل الذي يغادر عنده عقار الميثادون جسم الإنسان. ومن المستبعد أن يؤثر هذا في غالبية مستخدمي عقار ميثادون.</p><p dir="RTL"><strong>تناول عقار ريوسيجوات مع عقار زياجين:</strong></p><p dir="RTL">إذا كنت تتناول عقار ريوسيجوات&nbsp; (وهو دواء يستخدم لعلاج ارتفاع ضغط الدم في الأوعية الدموية (الشرايين الرئوية) المسؤولة عن إيصال الدم من القلب إلى الرئتين)، فقد&nbsp; يحتاج&nbsp; الطبيب لتقليل جرعتك من عقار ريوسيجوات، حيث قد تؤدي مادة الأباكافير (وهي المادة الفعالة في عقار زياجين) إلى زيادة&nbsp; مستويات المادة الفعالة لعقار ريوسيجوات في الدم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;<strong>الحمل</strong><!--[if supportFields]><b><span
lang=EN-US style='font-size:13.0pt;font-family:"Arial",sans-serif;mso-fareast-font-family:
Arial;mso-fareast-language:AR-SA'><span style='mso-element:field-begin'></span></span></b><span
dir=LTR></span><span dir=LTR></span><b><span lang=EN-US dir=LTR
style='font-size:13.0pt;font-family:"Arial",sans-serif;mso-fareast-font-family:
Arial;mso-fareast-language:AR-SA'><span dir=LTR></span><span dir=LTR></span>
DOCVARIABLE VAULT_ND_29ca8c77-f3f5-4c5d-a207-9617eeb615b2 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
lang=EN-US style='font-size:13.0pt;font-family:"Arial",sans-serif;mso-fareast-font-family:
Arial;mso-fareast-language:AR-SA'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p dir="RTL">إذا كنتِ <strong>حاملاً</strong>، أو <strong>تظنين أنكِ حامل</strong>، أو كنتِ <strong>تنوين الحمل</strong> <strong>فلا ينبغي استخدام زياجين</strong> دون استشارة الطبيب. سوف يقدّر <strong>الطبيب</strong> الفائدة التي تعود عليك في مقابل الخطر الذي قد يهدد الجنين عند تناول زياجين أثناء الحمل.</p><p dir="RTL">في حال تعرض الجنين أو الوليد للأدوية غير النيوكليوزيدية المضادة لأنزيم المنتسخة (NRTIs) أثناء الحمل أو الولادة، يمكن في هذه الحالة ملاحظة زيادة طفيفة مؤقتة لمادة اللاكتات في مستويات الدم. وعلاوة على ذلك قد تكون هناك حالات نادرة جدًا لأمراض تؤثر على الجهاز العصبي كما في تأخر التطور والنوبات. وبوجه عام في الأطفال الذين تتناول أمهاتهم الأدوية غير النيوكليوزيدية المضادة لأنزيم المنتسخة (NRTIs) أثناء الحمل، نجد أن الفائدة التي تتمثل في تقليل فرص الإصابة بمرض نقص المناعة البشرية أكبر من احتمال الإصابة بأعراض جانبية.</p><p dir="RTL"><strong>الرضاعة</strong><!--[if supportFields]><b><span
lang=EN-US style='font-size:13.0pt;font-family:"Arial",sans-serif;mso-fareast-font-family:
Arial;mso-fareast-language:AR-SA'><span style='mso-element:field-begin'></span></span></b><span
dir=LTR></span><span dir=LTR></span><b><span lang=EN-US dir=LTR
style='font-size:13.0pt;font-family:"Arial",sans-serif;mso-fareast-font-family:
Arial;mso-fareast-language:AR-SA'><span dir=LTR></span><span dir=LTR></span>
DOCVARIABLE VAULT_ND_d105db64-8d3c-46db-a3db-328437e8eabd \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
lang=EN-US style='font-size:13.0pt;font-family:"Arial",sans-serif;mso-fareast-font-family:
Arial;mso-fareast-language:AR-SA'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p dir="RTL"><strong>ينبغي للأمهات المصابات بفيروس نقص المناعة البشرية تجنب إرضاع أطفالهن رضاعة طبيعية إن أمكن</strong>؛ وذلك لأنه يمكن انتقال عدوى فيروس نقص المناعة البشرية إلى الطفل عبر لبن الأم. في حال تعذر الرضاعة الصناعية، ينبغي استشارة الطبيب.</p><p dir="RTL">يمكن أيضًا أن تنتقل كمية بسيطة من مكونات زياجين إلى الطفل عبر لبن الأم.</p><p dir="RTL">&ccedil;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>تحدثي إلى الطبيب على الفور</strong> إذا كنتِ ترضعين طفلك رضاعة طبيعية أو تفكرين في ذلك.</p><p dir="RTL"><strong>أثناء تناولك زياجين</strong><!--[if supportFields]><b><span
lang=AR-SA style='font-size:12.0pt;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";mso-fareast-language:AR-SA'><span
style='mso-element:field-begin'></span> </span></b><b><span lang=EN-US dir=LTR
style='font-size:12.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
"Times New Roman";mso-fareast-language:AR-SA'>DOCVARIABLE</span></b><span
dir=RTL></span><span dir=RTL></span><b><span lang=EN-US style='font-size:12.0pt;
font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-fareast-language:AR-SA'><span dir=RTL></span><span dir=RTL></span> </span></b><b><span
lang=EN-US dir=LTR style='font-size:12.0pt;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";mso-fareast-language:AR-SA'>VAULT_ND_0747fb10-a616-45b9-bc32-1dfe04ee51ef
\* MERGEFORMAT</span></b><span dir=RTL></span><span dir=RTL></span><b><span
lang=EN-US style='font-size:12.0pt;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";mso-fareast-language:AR-SA'><span
dir=RTL></span><span dir=RTL></span> </span></b><b><span lang=AR-SA
style='font-size:12.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
"Times New Roman";mso-fareast-language:AR-SA'><span style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
lang=AR-SA style='font-size:12.0pt;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";mso-fareast-language:AR-SA'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p dir="RTL"><strong>ستحتاج إلى إجراء فحوصات دم دورية</strong><!--[if supportFields]><b><span
lang=EN-US style='font-size:12.0pt;line-height:142%;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";mso-fareast-language:AR-SA'><span
style='mso-element:field-begin'></span></span></b><span dir=LTR></span><span
dir=LTR></span><b><span lang=EN-US dir=LTR style='font-size:12.0pt;line-height:
142%;font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-fareast-language:AR-SA'><span dir=LTR></span><span dir=LTR></span>
DOCVARIABLE VAULT_ND_1039fc20-fa87-4f06-ac87-a463d810b949 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
lang=EN-US style='font-size:12.0pt;line-height:142%;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";mso-fareast-language:AR-SA'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p dir="RTL">طوال مدة تناول زياجين، سوف يرتّب الطبيب أمر إجراء فحوصات الدم الدورية للتحقق من الأعراض الجانبية. يمكن الحصول على المزيد من المعلومات حول هذه الأعراض الجانبية في <strong>القسم</strong> <strong>٤</strong> من هذه النشرة.</p><p dir="RTL"><strong>تواصل بانتظام مع طبيبك</strong><!--[if supportFields]><b><span lang=EN-US
style='font-size:12.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
"Times New Roman";mso-fareast-language:AR-SA'><span style='mso-element:field-begin'></span></span></b><span
dir=LTR></span><span dir=LTR></span><b><span lang=EN-US dir=LTR
style='font-size:12.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
"Times New Roman";mso-fareast-language:AR-SA'><span dir=LTR></span><span
dir=LTR></span> DOCVARIABLE VAULT_ND_fbbda3ca-fe80-4334-b099-40be953f038a \*
MERGEFORMAT <span style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
lang=EN-US style='font-size:12.0pt;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";mso-fareast-language:AR-SA'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p dir="RTL">يساعد زياجين في التحكم في حالتك الصحية. ويجب عليك تناوله يوميًا لمنع تفاقم المرض. قد تصاب بعدوى وأمراض أخرى ترتبط بعدوى الإيدز (فيروس نقص المناعة البشرية).</p><p dir="RTL">&ccedil;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>ابق على اتصال بالطبيب ولا تتوقف عن تناول </strong><strong>زياجين</strong> بدون مشورته.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>تناول زياجين دائمًا وفق الجرعة التي يحددها لك الطبيب</strong>. استشر الطبيب أو الصيدلي في حالة الشك بشأن طريقة استعماله على الوجه الصحيح.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الجرعة</strong><!--[if supportFields]><b><span lang=EN-US
style='font-size:13.0pt;font-family:"Arial",sans-serif;mso-fareast-font-family:
Arial;mso-fareast-language:AR-SA'><span style='mso-element:field-begin'></span></span></b><span
dir=LTR></span><span dir=LTR></span><b><span lang=EN-US dir=LTR
style='font-size:13.0pt;font-family:"Arial",sans-serif;mso-fareast-font-family:
Arial;mso-fareast-language:AR-SA'><span dir=LTR></span><span dir=LTR></span>
DOCVARIABLE VAULT_ND_11ad8fac-4604-4c03-adc3-6915947e018c \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
lang=EN-US style='font-size:13.0pt;font-family:"Arial",sans-serif;mso-fareast-font-family:
Arial;mso-fareast-language:AR-SA'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p dir="RTL">الجرعة المعتادة من زياجين لدى البالغين والأطفال الذين يبلغ وزنهم ٢٥ كجم على الأقل هي ٦٠٠ ملجم في اليوم. ويجوز تناولها على هيئة ٣٠٠ ملجم (قرص واحد) مرتين في اليوم، أو ٦٠٠ ملجم (قرصان) مرة واحدة في اليوم، حسب تعليمات الطبيب.</p><p dir="RTL">الجرعة المعتادة من زياجين لدى أطفال يزيد وزنهم عن ٢٠ كجم ويقل عن ٢٥ كجم هي ٤٥٠ ملجم في اليوم. ويجوز تناولها على هيئة ١٥٠ ملجم (نصف قرص) في الصباح و٣٠٠ ملجم (قرص كامل) في المساء، أو ٤٥٠ ملجم (قرص ونصف القرص) مرة واحدة في اليوم، حسب تعليمات الطبيب.</p><p dir="RTL">الجرعة المعتادة من زياجين لدى أطفال يزيد وزنهم عن ١٤ كجم ويقل عن ٢٠ كجم هي ٣٠٠ ملجم في اليوم. ويجوز تناولها على هيئة ١٥٠ ملجم (نصف قرص) مرتين في اليوم، أو ٣٠٠ ملجم (قرص كامل) مرة واحدة في اليوم، حسب تعليمات الطبيب.</p><p dir="RTL">زياجين متوفر أيضًا على هيئة محلول للإعطاء عن طريق الفم (٢٠ ملجم/مل) ويمكن وصفه بواسطة الطبيب إذا كنت بحاجة لجرعة أقل من المعتاد أو إذا كنت غير قادر على تناول الأقراص.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>كيفية تناول الجرعة</strong><!--[if supportFields]><b><span
lang=EN-US style='font-size:13.0pt;font-family:"Arial",sans-serif;mso-fareast-font-family:
Arial;mso-fareast-language:AR-SA'><span style='mso-element:field-begin'></span></span></b><span
dir=LTR></span><span dir=LTR></span><b><span lang=EN-US dir=LTR
style='font-size:13.0pt;font-family:"Arial",sans-serif;mso-fareast-font-family:
Arial;mso-fareast-language:AR-SA'><span dir=LTR></span><span dir=LTR></span>
DOCVARIABLE VAULT_ND_ed2a0a6b-d51f-405a-b385-01234a5ee671 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
lang=EN-US style='font-size:13.0pt;font-family:"Arial",sans-serif;mso-fareast-font-family:
Arial;mso-fareast-language:AR-SA'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p dir="RTL">احرص على تناول زياجين على النحو الذي نصحك به الطبيب، وانتبه جيدًا كي لا تفوتك أي جرعة قدر الإمكان. كما يجب عليك مراجعة الطبيب أو الصيدلاني إذا لم تكن واثقًا من هذا الشأن.</p><p dir="RTL">إذا أراد الطبيب تخفيض جرعة زياجين، على سبيل المثال إذا كنت تعاني من مشاكل كبدية، حينها قد يوصف لك الأباكاﭬـير على هيئة محلول للإعطاء عن طريق الفم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>في حالة نسيان تناول جرعة زياجين</strong><!--[if supportFields]><b><span
lang=EN-US style='font-size:13.0pt;font-family:"Arial",sans-serif;mso-fareast-font-family:
Arial;mso-fareast-language:AR-SA'><span style='mso-element:field-begin'></span></span></b><span
dir=LTR></span><span dir=LTR></span><b><span lang=EN-US dir=LTR
style='font-size:13.0pt;font-family:"Arial",sans-serif;mso-fareast-font-family:
Arial;mso-fareast-language:AR-SA'><span dir=LTR></span><span dir=LTR></span>
DOCVARIABLE VAULT_ND_b7f7e921-f650-44e0-8dfc-96c2ad047b3c \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
lang=EN-US style='font-size:13.0pt;font-family:"Arial",sans-serif;mso-fareast-font-family:
Arial;mso-fareast-language:AR-SA'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p dir="RTL"><strong>لا تتناول جرعة مضاعفة</strong> لتعويض الجرعة التي فاتتك. فقط تناولها فور تذكرها.</p><p dir="RTL">إذا لم تكن واثقًا بشأن الإجراء الذي يجب أن تتخذه، استشر الطبيب أو الصيدلاني</p><p dir="RTL"><strong>في حالة تناول جرعة زائدة عن اللزوم من زياجين</strong><!--[if supportFields]><b><span
lang=EN-US style='font-size:13.0pt;font-family:"Arial",sans-serif;mso-fareast-font-family:
Arial;mso-fareast-language:AR-SA'><span style='mso-element:field-begin'></span></span></b><span
dir=LTR></span><span dir=LTR></span><b><span lang=EN-US dir=LTR
style='font-size:13.0pt;font-family:"Arial",sans-serif;mso-fareast-font-family:
Arial;mso-fareast-language:AR-SA'><span dir=LTR></span><span dir=LTR></span>
DOCVARIABLE VAULT_ND_3298c2a6-69b6-40a3-a681-4ed457b1b92e \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
lang=EN-US style='font-size:13.0pt;font-family:"Arial",sans-serif;mso-fareast-font-family:
Arial;mso-fareast-language:AR-SA'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p dir="RTL">إذا تناولت جرعة أكبر مما يجب تناوله من زياجين أقراص أو محلول للإعطاء عن طريق الفم، <strong>يجب الاتصال بالطبيب أو الصيدلي، أو الذهاب إلى قسم الطوارئ بأقرب مستشفى للاستشارة</strong>. ويُفضل أن تريهم عبوة زياجين إن أمكن.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>لا تتوقف عن تناول زياجين دون استشارة الطبيب</strong><!--[if supportFields]><b><span
lang=EN-US style='font-size:13.0pt;font-family:"Arial",sans-serif;mso-fareast-font-family:
Arial;mso-fareast-language:AR-SA'><span style='mso-element:field-begin'></span></span></b><span
dir=LTR></span><span dir=LTR></span><b><span lang=EN-US dir=LTR
style='font-size:13.0pt;font-family:"Arial",sans-serif;mso-fareast-font-family:
Arial;mso-fareast-language:AR-SA'><span dir=LTR></span><span dir=LTR></span>
DOCVARIABLE VAULT_ND_5fb4a053-6028-49cd-9c05-155ea57e589e \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
lang=EN-US style='font-size:13.0pt;font-family:"Arial",sans-serif;mso-fareast-font-family:
Arial;mso-fareast-language:AR-SA'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p dir="RTL">في حال التوقف عن تناول زياجين لأي سبب من الأسباب، خاصةً إذا كنت تعتقد بإصابتك ببعض الأعراض الجانبية أو أي مرض آخر، فلا بد من استشارة الطبيب قبل استئناف تناول الدواء. في بعض الأحيان يطلب منك الطبيب استئناف تناول زياجين مرة أخرى في مكان يسهل فيه الحصول على العناية الطبية إن لزم الأمر.</p><p dir="RTL">إذا كنت مصابًا بالتهاب الكبد الوبائي (بي) فلا تتوقف عن تناول زياجين بدون مشورة الطبيب إذ قد يعاودك التهاب الكبد.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثله مثل جميع الأدوية، يمكن أن يتسبب زياجين في آثار جانبية، إلا أنها لا تصيب الجميع.</p><p dir="RTL">أثناء العلاج من فيروس نقص المناعة البشرية، قد يصعب تحديد ما إذا كان أي عرض يطرأ هو أثر جانبي لتناول دواء زياجين أو أي أدوية أخرى تتناولها، أم أثر طبيعي لفيروس نقص المناعة البشرية ذاته. <strong>لذا من المهم جدًا استشارة الطبيب عندما تطرأ أي تغيرات في صحتك.</strong></p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL">يمكن أن يتسبب زياجين في رد فعل تحسسي خطير يُعرف بتفاعل فرط الحساسية، راجع &quot;تفاعلات فرط الحساسية&quot; في &quot;<em>حالات ينبغي الانتباه لها</em>&quot; في <strong>القسم </strong><strong>٤</strong>.</p><p dir="RTL">&nbsp;</p><p dir="RTL">من المهم جدًا قراءة المعلومات المتعلقة بهذا التفاعل الخطير وفهمها جيدًا.</p></td></tr></tbody></table><p dir="RTL"><strong>علاوة على الآثار الجانبية الموضحة أدناه لدواء زياجين</strong>، يمكن أن تتطور بعض الحالات الأخرى أثناء العلاج المركب لفيروس نقص المناعة البشرية.</p><p dir="RTL">من الضروري قراءة المعلومات الواردة في <em>&quot;حالات ينبغي الانتباه لها&quot;</em> في <strong>القسم</strong> <strong>٤</strong>.</p><p dir="RTL"><strong>حالات ينبغي الانتباه لها</strong><!--[if supportFields]><b><span
lang=EN-US style='font-size:13.0pt;font-family:"Arial",sans-serif;mso-fareast-font-family:
Arial;mso-fareast-language:AR-SA'><span style='mso-element:field-begin'></span></span></b><span
dir=LTR></span><span dir=LTR></span><b><span lang=EN-US dir=LTR
style='font-size:13.0pt;font-family:"Arial",sans-serif;mso-fareast-font-family:
Arial;mso-fareast-language:AR-SA'><span dir=LTR></span><span dir=LTR></span>
DOCVARIABLE VAULT_ND_3b418eda-c2f5-440a-9ad2-208ec2ee73aa \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
lang=EN-US style='font-size:13.0pt;font-family:"Arial",sans-serif;mso-fareast-font-family:
Arial;mso-fareast-language:AR-SA'><span style='mso-element:field-end'></span></span></b><![endif]--></p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><strong>تفاعلات فرط الحساسية</strong></p><p dir="RTL">يحتوي زياجين على <strong>أباكاﭬـير</strong> (وهو أيضًا مكوّن فعال في <strong>تريزيـﭭـير </strong>و<strong>كيـﭭـيكسا </strong>و<strong>ترايوميك</strong>).</p><p dir="RTL">وقد يسبب أباكاﭬـير تفاعلات حساسية خطيرة (تعرف باسم تفاعلات فرط الحساسية)، والتي يمكن أن تهدد حياة الشخص في حالة عدم التوقف عن العلاج باستخدام المنتجات التي تحتوي على أباكاﭬـير.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>من الذي يتعرض لهذه التفاعلات؟</strong><!--[if supportFields]><b><span
  lang=EN-US style='font-size:12.0pt;font-family:"Times New Roman",serif;
  mso-fareast-font-family:"Times New Roman";mso-fareast-language:AR-SA'><span
  style='mso-element:field-begin'></span></span></b><span dir=LTR></span><span
  dir=LTR></span><b><span lang=EN-US dir=LTR style='font-size:12.0pt;
  font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-fareast-language:AR-SA'><span dir=LTR></span><span dir=LTR></span>
  DOCVARIABLE VAULT_ND_1c820034-b20d-4511-a7fb-bc08c6f1e17c \* MERGEFORMAT <span
  style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
  lang=EN-US style='font-size:12.0pt;font-family:"Times New Roman",serif;
  mso-fareast-font-family:"Times New Roman";mso-fareast-language:AR-SA'><span
  style='mso-element:field-end'></span></span></b><![endif]--></p><p dir="RTL">يمكن أن يعاني أي شخص يتناول زياجين من تفاعل فرط الحساسية، وهو الأمر الذي يمكنه تهديد حياته إذا استمر في تناول زياجين.</p><p dir="RTL">ويزيد احتمال التعرض لهذا التفاعل في حالة وجود جين يطلق عليه اسم <strong>HLA-B*5701</strong> (ويظل احتمال الإصابة قائمًا حتى في عدم وجود هذا الجين). إذا أمكن سوف يتم فحصك لتحديد وجود هذا الجين قبل وصف زياجين لك. <strong>إذا كنت على علم بوجود هذا الجين لديك، فأخبر الطبيب قبل تناول زياجين.</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&lrm;</strong><strong>ما هي الأعراض؟</strong><!--[if supportFields]><b><span lang=EN-US
  style='font-size:12.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
  "Times New Roman";mso-fareast-language:AR-SA'><span style='mso-element:field-begin'></span></span></b><span
  dir=LTR></span><span dir=LTR></span><b><span lang=EN-US dir=LTR
  style='font-size:12.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
  "Times New Roman";mso-fareast-language:AR-SA'><span dir=LTR></span><span
  dir=LTR></span> DOCVARIABLE VAULT_ND_83ec6bff-a092-4d89-95e7-835cd08937da \*
  MERGEFORMAT <span style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
  lang=EN-US style='font-size:12.0pt;font-family:"Times New Roman",serif;
  mso-fareast-font-family:"Times New Roman";mso-fareast-language:AR-SA'><span
  style='mso-element:field-end'></span></span></b><![endif]--></p><p dir="RTL">أكثر الأعراض شيوعًا هي:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>الحمى</strong> (ارتفاع درجات الحرارة) <strong>والطفح الجلدي</strong>.</p><p dir="RTL">الأعراض الشائعة الأخرى هي:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الغثيان (الشعور بالتوعك)، القيء، الإسهال، ألم في المعدة، الإعياء الشديد، ضيق النفس، السعال، الصداع، ألم في العضلات، والشعور بالضيق.</p><p dir="RTL">ومن بين الأعراض الأخرى الأقل شيوعًا:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام المفاصل، وتورم الرقبة، ومشاكل حادة في التنفس، وإلتهاب الحلق.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في بعض الأحيان يحدث التهاب في العين <em>(التهاب الملتحمة)</em>، وتقرحات في الفم، وانخفاض في ضغط الدم، ووخز أو تنميل في اليدين أو القدمين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>متى تحدث هذه التفاعلات؟</strong><!--[if supportFields]><b><span
  lang=EN-US style='font-size:12.0pt;font-family:"Times New Roman",serif;
  mso-fareast-font-family:"Times New Roman";mso-fareast-language:AR-SA'><span
  style='mso-element:field-begin'></span></span></b><span dir=LTR></span><span
  dir=LTR></span><b><span lang=EN-US dir=LTR style='font-size:12.0pt;
  font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-fareast-language:AR-SA'><span dir=LTR></span><span dir=LTR></span>
  DOCVARIABLE VAULT_ND_a828059c-28e7-4034-ac24-833e8b7a75ed \* MERGEFORMAT <span
  style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
  lang=EN-US style='font-size:12.0pt;font-family:"Times New Roman",serif;
  mso-fareast-font-family:"Times New Roman";mso-fareast-language:AR-SA'><span
  style='mso-element:field-end'></span></span></b><![endif]--></p><p dir="RTL">يمكن أن تظهر تفاعلات فرط الحساسية في أي وقت خلال فترة العلاج باستخدام زياجين ولكن الغالب وقوعها في الأسابيع الستة الأولى.</p><p dir="RTL"><strong>اتصل بالطبيب فورًا:</strong><!--[if supportFields]><b><span
  lang=EN-US style='font-size:12.0pt;font-family:"Times New Roman",serif;
  mso-fareast-font-family:"Times New Roman";mso-fareast-language:AR-SA'><span
  style='mso-element:field-begin'></span></span></b><span dir=LTR></span><span
  dir=LTR></span><b><span lang=EN-US dir=LTR style='font-size:12.0pt;
  font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-fareast-language:AR-SA'><span dir=LTR></span><span dir=LTR></span>
  DOCVARIABLE VAULT_ND_9e2e1375-25ec-4824-b184-cb471186edef \* MERGEFORMAT <span
  style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
  lang=EN-US style='font-size:12.0pt;font-family:"Times New Roman",serif;
  mso-fareast-font-family:"Times New Roman";mso-fareast-language:AR-SA'><span
  style='mso-element:field-end'></span></span></b><![endif]--></p><p dir="RTL"><strong>1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>في حالة ظهور طفح جلدي أو</strong></p><p dir="RTL"><strong>2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>إذا ظهرت لديك أعراض مجموعتين على الأقل من المجموعات التالية:</strong></p><p dir="RTL">-&nbsp;&nbsp; الحمى</p><p dir="RTL">-&nbsp;&nbsp; ضيق النفس أو التهاب الحلق أو السعال</p><p dir="RTL">-&nbsp;&nbsp; الغثيان أو القيء أو الإسهال أو ألم في المعدة</p><p dir="RTL">-&nbsp;&nbsp; الإعياء أو الألم الشديد أو الشعور بالتعب عامة</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد ينصحك الطبيب بالتوقف عن تناول زياجين</p><p dir="RTL"><strong>احتفظ دومًا ببطاقة التنبيه في حوزتك أثناء تناول زياجين.</strong><!--[if supportFields]><b><span
  lang=EN-US style='font-size:12.0pt;font-family:"Times New Roman",serif;
  mso-fareast-font-family:"Times New Roman";mso-fareast-language:AR-SA'><span
  style='mso-element:field-begin'></span></span></b><span dir=LTR></span><span
  dir=LTR></span><b><span lang=EN-US dir=LTR style='font-size:12.0pt;
  font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-fareast-language:AR-SA'><span dir=LTR></span><span dir=LTR></span>
  DOCVARIABLE VAULT_ND_c96cf1b4-f899-4822-9706-e1ed7ce2e82e \* MERGEFORMAT <span
  style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
  lang=EN-US style='font-size:12.0pt;font-family:"Times New Roman",serif;
  mso-fareast-font-family:"Times New Roman";mso-fareast-language:AR-SA'><span
  style='mso-element:field-end'></span></span></b><![endif]--></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>في حالة التوقف عن تناول زياجين</strong><!--[if supportFields]><b><span
  lang=EN-US style='font-size:12.0pt;font-family:"Times New Roman",serif;
  mso-fareast-font-family:"Times New Roman";mso-fareast-language:AR-SA'><span
  style='mso-element:field-begin'></span></span></b><span dir=LTR></span><span
  dir=LTR></span><b><span lang=EN-US dir=LTR style='font-size:12.0pt;
  font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-fareast-language:AR-SA'><span dir=LTR></span><span dir=LTR></span>
  DOCVARIABLE VAULT_ND_68620cff-f74a-4712-9edf-bb4874df417d \* MERGEFORMAT <span
  style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
  lang=EN-US style='font-size:12.0pt;font-family:"Times New Roman",serif;
  mso-fareast-font-family:"Times New Roman";mso-fareast-language:AR-SA'><span
  style='mso-element:field-end'></span></span></b><![endif]--></p><p dir="RTL">إذا توقفت عن تناول زياجين بسبب تفاعل فرط الحساسية، <strong>فيجب عليك عدم تناول زياجين مرة أخرى على الإطلاق، أو أي دواء آخر يحتوي على أباكاﭬـير (مثل كيـﭭـيكسا أو تريزيـﭭـير أو ترايوميك).</strong> فإن حدث وتناولت الدواء، فمن الممكن أن يحدث انخفاض حاد في ضغط الدم يؤدي إلى الوفاة.</p><p dir="RTL">في حال التوقف عن تناول زياجين لأي سبب من الأسباب - خاصة إذا كنت تعتقد إصابتك ببعض الأعراض الجانبية أو أي مرض آخر:</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>فلا بد من استشارة الطبيب قبل استئناف تناول الدواء</strong>. سوف يتحقق الطبيب من علاقة هذه الأعراض بتفاعل فرط الحساسية. إذا رأى الطبيب أن هذه الأعراض قد تكون مرتبطة بالحساسية، <strong>فسوف يطلب منك عدم تناول زياجين مجددًا وكذلك أي دواء يحتوي على أباكاﭬـير. </strong>من المهم الالتزام بهذه النصيحة.</p><p dir="RTL">فأحيانًا تظهر هذه التفاعلات لدى المرضى الذين بدأوا في تناول أباكاﭬـير مجددًا وسبق أن احتوت بطاقة التنبيه لديهم على واحد من هذه الأعراض قبل التوقف عن تناوله.</p><p dir="RTL">ويندر ظهور هذه التفاعلات لدى المرضى الذين بدأوا في تناول أباكاﭬـير مجددًا ولم يسبق أن احتوت بطاقة التنبيه لديهم على واحد من هذه الأعراض قبل التوقف عن تناوله.</p><p dir="RTL">إذا نصحك الطبيب باستئناف تناول زياجين مرة أخرى، فقد يُطلب منك تناول الجرعات الأولى في مكان يسهل فيه الحصول على العناية الطبية إذا لزم الأمر.</p><p dir="RTL">إذا كنت تعاني من فرط الحساسية لعقار زياجين، فأعد جميع الأقراص غير المستخدمة من زياجين حتى يتم التخلص منها بشكل آمن. يجب استشارة الطبيب أو الصيدلي.</p><p dir="RTL">تحتوي عبوة زياجين على <strong>بطاقة تنبيه</strong>، لتذكيرك أنت والطاقم الطبي لديك بتفاعلات فرط الحساسية. <strong>انزع هذه البطاقة واحتفظ بها معك طوال الوقت</strong>.</p></td></tr></tbody></table><p dir="RTL">يمكن أن يؤدي العلاج المركب مثل دواء زياجين إلى تطور حالات أخرى أثناء علاج فيروس نقص المناعة البشرية.</p><p dir="RTL"><strong>احتمال نشاط الإصابات السابقة</strong><!--[if supportFields]><b><span
lang=EN-US style='font-size:12.0pt;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";mso-fareast-language:AR-SA'><span
style='mso-element:field-begin'></span></span></b><span dir=LTR></span><span
dir=LTR></span><b><span lang=EN-US dir=LTR style='font-size:12.0pt;font-family:
"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";mso-fareast-language:
AR-SA'><span dir=LTR></span><span dir=LTR></span> DOCVARIABLE
VAULT_ND_3de04765-80f9-4ac9-8c85-2ac070ab4503 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
lang=EN-US style='font-size:12.0pt;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";mso-fareast-language:AR-SA'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p dir="RTL">بالنسبة للمرضى المصابين بحالة متقدمة من عدوى فيروس نقص المناعة البشرية (الإيدز) يكون الجهاز المناعي عندهم ضعيفًا ويصبحون أكثر عرضة للإصابة بعدوى خطيرة (عدوى انتهازية). وعند بدء العلاج، ربما يلاحظ المرضى نشاط العدوى القديمة التي اختفت مسببةً ظهورعلامات وأعراض الالتهاب. ويتسبب عادةً في ظهور هذه الأعراض قوة جهاز المناعة بالجسم؛ حيث يمنح الجسم قوة لمكافحة هذه العدوى.</p><p dir="RTL">في حال ظهور أي من أعراض العدوى أثناء تناول زياجين:</p><p dir="RTL"><strong>أخبر طبيبك في الحال</strong>. ولا تتناول أي أدوية أخرى لعلاج العدوى بدون استشارة الطبيب.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يعتبر الحماض اللاكتيكي من الآثار الجانبية النادرة والخطيرة في الوقت نفسه</strong><!--[if supportFields]><b><span lang=EN-US
style='font-size:12.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
"Times New Roman";mso-fareast-language:AR-SA'><span style='mso-element:field-begin'></span></span></b><span
dir=LTR></span><span dir=LTR></span><b><span lang=EN-US dir=LTR
style='font-size:12.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
"Times New Roman";mso-fareast-language:AR-SA'><span dir=LTR></span><span
dir=LTR></span> DOCVARIABLE VAULT_ND_d6157203-85bd-44ae-955d-dc1e0b399cfa \*
MERGEFORMAT <span style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
lang=EN-US style='font-size:12.0pt;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";mso-fareast-language:AR-SA'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p dir="RTL">يعاني بعض المرضى الذين يتناولون دواء زياجين أو دواءً آخر مماثلاً له (كالأدوية النيوكليوزيدية المضادة لأنزيم المنتسخة المعاكس) من حالة مرضية تُعرف باسم الحماض اللاكتيكي علاوة على تضخم في الكبد.</p><p dir="RTL">والحماض اللاكتيكي هو حالة طبية تحدث نتيجة تراكم حمض اللاكتيك في الجسم. وهي حالة نادرة، لكن إن حدثت، فهي تظهر عادةً بعد عدة أشهر من العلاج. ويمكن أن تمثل خطورة على حياة الإنسان وتسبب قصورًا في الأعضاء الداخلية.</p><p dir="RTL">ويشيع حدوث الحماض اللاكتيكي لدى مرضى الكبد وخاصة النساء.</p><p dir="RTL">من بين علامات الحماض اللاكتيكي:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التنفس بعمق وصعوبة وسرعة في التنفس</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; النعاس</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تنميل أو ضعف في الأطراف</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالتوعك (الغثيان)، الإعياء (القيء)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم المعدة</p><p dir="RTL">خلال فترة العلاج سوف يراقب الطبيب ظهور أي علامات للحماض اللاكتيكي. إذا شعرت بأي من الأعراض المذكورة أعلاه أو أعراض أخرى تقلقك:</p><p dir="RTL">&ccedil; توجه إلى الطبيب في أقرب وقت ممكن.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الآثار الجانبية الشائعة</strong><!--[if supportFields]><b><span
lang=EN-US style='font-size:12.0pt;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";mso-fareast-language:AR-SA'><span
style='mso-element:field-begin'></span></span></b><span dir=LTR></span><span
dir=LTR></span><b><span lang=EN-US dir=LTR style='font-size:12.0pt;font-family:
"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";mso-fareast-language:
AR-SA'><span dir=LTR></span><span dir=LTR></span> DOCVARIABLE
VAULT_ND_4b9886be-0f5b-4564-85ea-879e8e1a8c8e \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
lang=EN-US style='font-size:12.0pt;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";mso-fareast-language:AR-SA'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p dir="RTL">يمكن أن تصيب <strong>حتى شخص واحد من كل ١٠ أشخاص</strong>:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالتوعك <em>(الغثيان)</em></p><p dir="RTL"><em>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>تفاعل فرط الحساسية <em>(راجع قسم &quot;تفاعلات فرط الحساسية&quot; أعلاه)</em></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإعياء <em>(القيء)</em></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إسهال</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الشهية</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإجهاد وفقدان الطاقة</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع درجة الحرارة <em>(الحمى)</em></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الطفح الجلدي</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الأعراض الجانبية النادرة</strong><!--[if supportFields]><b><span
lang=EN-US style='font-size:12.0pt;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";mso-fareast-language:AR-SA'><span
style='mso-element:field-begin'></span></span></b><span dir=LTR></span><span
dir=LTR></span><b><span lang=EN-US dir=LTR style='font-size:12.0pt;font-family:
"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";mso-fareast-language:
AR-SA'><span dir=LTR></span><span dir=LTR></span> DOCVARIABLE
VAULT_ND_5a4c270b-6b04-4448-bbf5-3bf66c6d01ff \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
lang=EN-US style='font-size:12.0pt;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";mso-fareast-language:AR-SA'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p dir="RTL">يمكن أن تصيب <strong>حتى شخص واحد من كل ١٠٠٠ شخص</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحماض اللاكتيكي (راجع القسم <em>&quot;&rlm;</em>‫<em>حالات ينبغي الانتباه لها&quot;</em>)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب في البنكرياس <em>(التهاب البنكرياس)</em></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية النادرة جدًا</strong><!--[if supportFields]><b><span lang=EN-US
style='font-size:12.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
"Times New Roman";mso-fareast-language:AR-SA'><span style='mso-element:field-begin'></span></span></b><span
dir=LTR></span><span dir=LTR></span><b><span lang=EN-US dir=LTR
style='font-size:12.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
"Times New Roman";mso-fareast-language:AR-SA'><span dir=LTR></span><span
dir=LTR></span> DOCVARIABLE VAULT_ND_ba163e37-14e5-4619-ae6e-7ae5608e2d60 \*
MERGEFORMAT <span style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
lang=EN-US style='font-size:12.0pt;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";mso-fareast-language:AR-SA'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p dir="RTL">يمكن أن تصيب <strong>حتى شخص واحد من كل ١٠٠٠٠ شخص</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي قد يسبب تقرحات ويبدو مثل الأهداف الصغيرة (بقع سوداء في المنتصف محاطة بمنطقة شاحبة مع حلقة سوداء حول الحافة) <em>(حُمامَى عديدة الأشكال)</em></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح واسع الانتشار مصاحب بتقرّح وتقشير في الجلد، وخاصةً حول الفم والأنف والعينين والأعضاء التناسلية <em>(متلازمة ستيفنز جونسون)</em> وشكل أكثر حدة يؤدي إلى تقشر الجلد في أكثر من ٣٠٪ من سطح الجسم (تقشر الأنسجة المتموتة البشروية التسممي)</p><p dir="RTL">&nbsp;</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL">إذا لاحظت أيًا من هذه الأعراض، فاتصل بالطبيب في الحال.</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>آثار أخرى قد تظهر في فحوصات الدم</strong><!--[if supportFields]><b><span
lang=EN-US style='font-size:12.0pt;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";mso-fareast-language:AR-SA'><span
style='mso-element:field-begin'></span></span></b><span dir=LTR></span><span
dir=LTR></span><b><span lang=EN-US dir=LTR style='font-size:12.0pt;font-family:
"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";mso-fareast-language:
AR-SA'><span dir=LTR></span><span dir=LTR></span> DOCVARIABLE
VAULT_ND_436d13de-8685-4312-83f0-f492c2ba2579 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
lang=EN-US style='font-size:12.0pt;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";mso-fareast-language:AR-SA'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p dir="RTL">يمكن أن يتسبب العلاج المركب لفيروس نقص المناعة البشرية أيضًا في حدوث:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع نسبة حمض اللاكتيك في الدم وهو ما قد يؤدي في حالات نادرة إلى الحُماض اللاكتيكي</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع مستويات السكر والدهون (الغلسريد والكوليسترول) في الدم</p><p>&nbsp;</p><p dir="RTL"><strong>في حالة الإصابة بالآثار الجانبية</strong><!--[if supportFields]><b><span
lang=EN-US style='font-size:13.0pt;font-family:"Arial",sans-serif;mso-fareast-font-family:
Arial;mso-fareast-language:AR-SA'><span style='mso-element:field-begin'></span></span></b><span
dir=LTR></span><span dir=LTR></span><b><span lang=EN-US dir=LTR
style='font-size:13.0pt;font-family:"Arial",sans-serif;mso-fareast-font-family:
Arial;mso-fareast-language:AR-SA'><span dir=LTR></span><span dir=LTR></span>
DOCVARIABLE VAULT_ND_dc6bb83b-d33b-413a-8b2c-2f17894a43c8 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
lang=EN-US style='font-size:13.0pt;font-family:"Arial",sans-serif;mso-fareast-font-family:
Arial;mso-fareast-language:AR-SA'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p dir="RTL">&ccedil;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>قم بإبلاغ الطبيب أو الصيدلاني</strong> في حالة <strong>تفاقم الآثار الجانبية أو إذا أصبحت مزعجة</strong>، أو إذا لاحظت آثارًا جانبية أخرى غير مبيَّنة في هذه النشرة</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">-&nbsp;&nbsp; يجب حفظ الدواء بعيدًا عن متناول ومرأى الأطفال.</p><p dir="RTL">-&nbsp;&nbsp; لا يجوز تناول زياجين بعد تاريخ الصلاحية المذكور على العبوة أو الزجاجة.</p><p dir="RTL">-&nbsp;&nbsp; يُحفظ زياجين في درجة حرارة أقل من ٣٠ درجة مئوية.</p><p dir="RTL">-&nbsp;&nbsp; لا يجوز التخلص من أقراص زياجين أو محلول زياجين الغير المرغوب بها في مياه الصرف الصحي أو المخلفات المنزلية. اسأل الصيدلي عن كيفية التخلّص من الأدوية التي لم تعد بحاجة إليها.&nbsp; فهذا من شأنه أن يساعد في الحفاظ على البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفعَّالة هي سلفات الأباكاﭬـير.</p><p dir="RTL">يحتوي كل قرص مغلَّف على ٣٠٠ ملجم سلفات الأباكاﭬـير.</p><p dir="RTL">المكونات الأخرى هي:</p><p dir="RTL"><em>لُب القرص</em></p><p dir="RTL">&rlm;‫سليلوز دقيق التبلور</p><p dir="RTL">جليكولات النشاء الصودي</p><p dir="RTL">سترات الماغنسيوم</p><p dir="RTL">‫السيليكا الغروانية اللامائية</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>غلاف القرص</em></p><p dir="RTL">تراياسيتين</p><p dir="RTL">هيدروكسي بروبيل ميثيل سليلوز</p><p dir="RTL">ثاني أكسيد التيتانيوم&rlm;‫</p><p dir="RTL">&rlm;‫بوليسوربات ٨٠</p><p dir="RTL">أكسيد حديد أصفر.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">لون الأقراص أصفر، وهي مميزة بعلامة للكسر وتتخذ شكل كبسولة وعليها رمز GX 623 على كلا الجانبين.<!--[if supportFields]><span
lang=AR-SA style='font-size:12.0pt;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";mso-fareast-language:AR-SA'><span
style='mso-element:field-begin'></span> </span><span lang=EN-US dir=LTR
style='font-size:12.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
"Times New Roman";mso-fareast-language:AR-SA'>DOCVARIABLE</span><span dir=RTL></span><span
dir=RTL></span><span lang=EN-US style='font-size:12.0pt;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";mso-fareast-language:AR-SA'><span
dir=RTL></span><span dir=RTL></span> </span><span lang=EN-US dir=LTR
style='font-size:12.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
"Times New Roman";mso-fareast-language:AR-SA'>VAULT_ND_ffcda78c-2282-4a77-8f45-7457e85ea39a
\* MERGEFORMAT</span><span dir=RTL></span><span dir=RTL></span><span
lang=EN-US style='font-size:12.0pt;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";mso-fareast-language:AR-SA'><span
dir=RTL></span><span dir=RTL></span> </span><span lang=AR-SA style='font-size:
12.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-fareast-language:AR-SA'><span style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=AR-SA style='font-size:12.0pt;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";mso-fareast-language:AR-SA'><span
style='mso-element:field-end'></span></span><![endif]--></p><p dir="RTL">&nbsp;</p><p dir="RTL">قد لا تتوفر جميع أشكال العبوات في كل الدول.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>زياجين</em> هو علامة تجارية مملوكة من أو مرخصة لمجموعة شركات ڤيڤ هيلثكير.</p><p dir="RTL">&copy;2023&nbsp;مجموعة شركات ڤيڤ للرعاية الصحية، جميع الحقوق محفوظة.</p><p dir="RTL">&nbsp;</p><table border="1" align="center" cellspacing="1" cellpadding="1" style="width:800px"><tbody><tr><td><p style="text-align:center"><strong>بطاقة التنبيه</strong><!--[if supportFields]><b><span lang=EN-US style='font-size:
12.0pt;line-height:107%;font-family:"Times New Roman",serif;mso-fareast-font-family:
"Times New Roman"'><span style='mso-element:field-begin'></span></span></b><span
dir=LTR></span><span dir=LTR></span><b><span lang=EN-US dir=LTR
style='font-size:12.0pt;line-height:107%;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman"'><span dir=LTR></span><span dir=LTR></span>
DOCVARIABLE VAULT_ND_b6bedffa-82fa-411c-82f7-a1b9b2c67d3e \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
lang=EN-US style='font-size:12.0pt;line-height:107%;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman"'><span style='mso-element:field-end'></span></span></b><![endif]--></p><table border="1" align="center" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td><p style="text-align:center"><strong>هام - بطاقة التنبيه</strong></p><p style="text-align:center"><strong>زياجين (سلفات أباكاﭬـير) أقراص أو محلول للإعطاء عن طريق الفم</strong></p><p style="text-align:center"><strong>احتفظ بهذه البطاقة معك طوال الوقت</strong></p></td></tr></tbody></table><p>بعض المرضى الذين يتناولون زياجين قد يظهر لديهم تفاعل فرط حساسية (تفاعل حساسية خطير) <strong>قد يهدد حياتهم</strong> إذا استمر العلاج بتناول زياجين. <strong>اتصل بطبيبك على الفور لاستشارته فيما يتعلق بالتوقف عن تناول </strong><strong>زياجين</strong><strong> في حالة:</strong></p><p dir="RTL">١<strong>)</strong>&nbsp; <strong>ظهر لديك طفح جلدي أو</strong></p><p dir="RTL">٢)&nbsp;<strong>إذا ظهر لديك واحد أو أكثر من أعراض مجموعتين على الأقل من المجموعات التالية</strong></p><p dir="RTL">- الحمى</p><p dir="RTL">-&nbsp; ضيق النفس أو التهاب الحلق أو السعال</p><p dir="RTL">-&nbsp; الغثيان أو القيء أو الإسهال أو ألم في البطن</p><p dir="RTL">-&nbsp; الإجهاد أو الألم الشديد، أو الشعور بالإعياء بشكل عام</p><p>إذا توقفت عن تناول زياجين بسبب حدوث هذا التفاعل، <strong>فيجب عليك عدم</strong> تناول زياجين <strong>على الإطلاق</strong>، أو أي دواء يحتوي على أباكاﭬـير (<em>كيڤيكسا أو تريزيڤير أو ترايوميك</em>) مرة أخرى، لأنه في خلال ساعات قد تتعرض لانخفاض ضغط الدم بشكل يهدد حياتك أو الوفاة.</p><p dir="RTL"><strong>اللوح الكرتوني </strong></p><p dir="RTL">يجب إدراج النص التالي في إحدى الألواح الكرتونية:</p><p dir="RTL"><strong>أخرج بطاقة التنبيه المرفقة، فهي تحتوي على معلومات مهمة حول السلامة.</strong></p><p dir="RTL">تحذير! في حالة ظهور أي من الأعراض التي تشير إلى حدوث تفاعلات فرط حساسية، اتصل بطبيبك على الفور.</p><p>&quot;<strong>اسحب هنا</strong>&quot; (مع إرفاق بطاقة التنبيه).</p></td></tr></tbody></table><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>الشركة المصنعة:</strong></p><p dir="RTL">ديلفارم بوزنان أسبولكا أكسيجنا، أولي. جرانڤالسكا 189، 60 - 322 بوزنان، بولندا</p><p dir="RTL"><strong>مالك ترخيص التسويق:</strong></p><p dir="RTL">جلاكسو العربية السعودية المحدودة* جًدة، السعودية.</p><p dir="RTL">العنوان: صندوق بريد 22617 ، جدة 21416 ، المملكة العربية السعودية.</p><p dir="RTL">*عضو في مجموعة شركات جلاكسو سميث كلاين.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            رقم إصدار: GDS33 
تاريخ الإصدار: ٢٠ يونيو ٢٠٢٢
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                ZIAGEN Film-coated scored tablets 300 mg abacavir.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each ZIAGEN tablet contains 300 mg of abacavir as abacavir sulfate. The scored tablets are yellow, biconvex, and capsule shaped. They are engraved with GX 623 on both sides.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated scored tablets.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>ZIAGEN</em> is indicated in antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus (HIV) infection in adults and children.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Therapy should be initiated by a physician experienced in the management of HIV infection.</p><p><em>ZIAGEN</em> can be taken with or without food.</p><p>To ensure administration of the entire dose, the tablet(s) should ideally be swallowed without crushing.</p><p>&nbsp;</p><p>For patients who are unable to swallow tablets, <em>Ziagen</em> is available as an oral solution. Alternatively, the tablets may be crushed and added to a small amount of semi-solid food or liquid, all of which should be consumed immediately <em>(see Pharmacokinetics)</em>.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Adults, adolescents and children weighing at least 25 kg</strong></p><p>The recommended dose of <em>ZIAGEN</em> tablets is 600 mg daily. This may be administered as either 300 mg (one tablet) twice daily or 600 mg (two tablets) once daily.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Children from three months and weighing less than 25 kg</strong></p><p><em>Children weighing 14 to &lt; 20 kg:</em> one-half of a scored abacavir tablet twice daily or one<strong> </strong>tablet taken once daily.</p><p><em>Children weighing </em>&ge; <em>20 kg to &lt; 25 kg:</em> one-half of a scored abacavir tablet taken in the morning and one whole tablet taken in the evening or one and a half tablets taken once daily.</p><p><em>Children weighing at least 25 kg</em>: the adult dosage of 300 mg twice daily or 600 mg once daily should be taken.</p><p>The oral solution may be administered to children weighing less than 14 kg or those who are unable to swallow tablets.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Children less than three months</strong></p><p>The data available on the use of <em>ZIAGEN</em> in this age group are very limited (<em>see Pharmacokinetics</em>).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Renal impairment</strong></p><p>No dosage adjustment of <em>ZIAGEN</em> is necessary in patients with renal dysfunction (<em>see Pharmacokinetics</em>).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Hepatic impairment</strong></p><p>Abacavir is metabolised primarily by the liver. The recommended dose of <em>ZIAGEN</em> in patients with mild hepatic impairment (Child-Pugh score 5 to 6) is 200&nbsp;mg (10&nbsp;ml) twice a day. To enable dose reduction <em>ZIAGEN</em> oral solution should be used for the treatment of these patients. Pharmacokinetic and safety data on the use of abacavir in patients with moderate and severe hepatic impairment are not available (<em>see Pharmacokinetics</em>). Therefore, the use of <em>ZIAGEN</em> is not recommended in patients with moderate or severe hepatic impairment, unless the benefit of use outweighs the risk.<strong><em> </em></strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                ZIAGEN is contraindicated in patients with known hypersensitivity to abacavir or any ingredient of ZIAGEN tablets or oral solution.
ZIAGEN is contraindicated in patients who have the HLA-B*5701 allele.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="1" cellspacing="1" cellpadding="1" style="width:800px"><tbody><tr><td><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Hypersensitivity</strong> (<em>see Adverse Reactions</em>)</p><p>Abacavir is associated with a risk for hypersensitivity reactions (HSR) characterized by fever and/or rash with other symptoms indicating multi-organ involvement. HSR can be life-threatening, and in rare cases fatal, when not managed appropriately. The risk for abacavir HSR to occur is significantly increased for patients who test positive for the <em>HLA-B*5701</em> allele. However, abacavir HSRs have been reported at a lower frequency in patients who do not carry this allele.&nbsp;</p><p><strong>The following should be adhered to:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Testing for <em>HLA-B*5701</em> status should be considered before initiating abacavir treatment and also before re-starting abacavir treatment in patients of unknown <em>HLA-B*5701</em> status who have previously tolerated abacavir.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>ZIAGEN</em> is not recommended for use in patients with the <em>HLA-B*5701</em> allele, or in patients who have had a suspected abacavir HSR while taking any other medicinal product containing abacavir (e.g. <em>KIVEXA</em>, <em>TRIZIVIR</em>, <em>TRIUMEQ</em>) regardless of <em>HLA-B*5701</em> status.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Each patient should be reminded to read the Patient Leaflet included in the <em>ZIAGEN</em> pack. They should be reminded of the importance of removing the Alert Card included in the pack, and keeping it with them at all times.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In any patient treated with <em>ZIAGEN</em>, the clinical diagnosis of suspected hypersensitivity reaction must remain the basis of clinical decision making.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong><em>ZIAGEN</em></strong><strong> must be stopped without delay, even in the absence of the HLA-B*5701 allele, if a HSR is suspected. Delay in stopping treatment with <em>ZIAGEN</em> after the onset of hypersensitivity may result in a life-threatening reaction.</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patients who have experienced a hypersensitivity reaction should be instructed to dispose of their remaining <em>ZIAGEN</em> tablets in order to avoid restarting abacavir.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Restarting abacavir containing products following a suspected abacavir HSR can result in a prompt return of symptoms within hours, and may include life-threatening hypotension and death.</strong></p><ul><li><strong>Regardless of a patient&rsquo;s <em>HLA-B*5701</em> status, if therapy with any abacavir containing product has been discontinued for any reason and restarting abacavir therapy is under consideration, the reason for discontinuation must be established.&nbsp; If HSR cannot be ruled out, <em>ZIAGEN</em> or any other medicinal product containing abacavir (e.g. <em>KIVEXA</em>, <em>TRIZIVIR</em>, <em>TRIUMEQ</em>) must not be restarted.</strong></li><li>If a hypersensitivity reaction is ruled out, patients may restart <em>ZIAGEN. </em>Rarely, patients who have stopped abacavir for reasons other than symptoms of HSR have also experienced life-threatening reactions within hours of re- initiating abacavir therapy (<em>see Section 4.8 Description of selected adverse reactions</em>). Patients must be made aware that HSR can occur with reintroduction of <em>ZIAGEN</em> or any other medicinal product containing abacavir (e.g. <em>KIVEXA</em>, <em>TRIZIVIR</em>, <em>TRIUMEQ</em>) and that reintroduction of <em>ZIAGEN</em> or any other medicinal product containing abacavir (e.g. <em>KIVEXA</em>, <em>TRIZIVIR</em>, <em>TRIUMEQ</em>) should be undertaken only if medical care can be readily accessed.</li></ul><p><em>Clinical Description of abacavir HSR: </em></p><p>Abacavir HSR has been well characterised through clinical studies and during post marketing follow-up. Symptoms usually appeared within the first six weeks (median time to onset 11 days) of initiation of treatment with abacavir, <strong>although these reactions may occur at any time during therapy.</strong></p><p>&nbsp;Almost all HSR to abacavir include fever and/or rash as part of the syndrome.</p><p>Other signs and symptoms that have been observed as part of abacavir HSR include respiratory and gastrointestinal symptoms, <strong>which may lead to misdiagnosis of HSR as respiratory disease (pneumonia, bronchitis, pharyngitis), or gastroenteritis </strong>(<em>see Adverse Reactions, Description of Selected Adverse Reactions</em>). The symptoms related to HSR worsen with continued therapy and can be life threatening. These symptoms usually resolve upon discontinuation of <em>ZIAGEN</em>.</p></td></tr></tbody></table></td></tr></tbody></table><p>&sect;&nbsp; <strong>Lactic Acidosis/Severe Hepatomegaly with Steatosis</strong></p><p>Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of&nbsp; antiretroviral nucleoside analogues either alone or in combination, including abacavir.&nbsp; A majority of these cases have been in women.&nbsp;</p><p>Clinical features which may be indicative of the development of lactic acidosis include generalised weakness, anorexia, and sudden unexplained weight loss, gastrointestinal symptoms and respiratory symptoms (dyspnoea and tachypnoea).</p><p>Caution should be exercised when administering <em>ZIAGEN</em>, particularly to those with known risk factors for liver disease. Treatment with <em>ZIAGEN</em> should be suspended in any patient who develops clinical or laboratory findings suggestive of lactic acidosis with or without hepatitis (which may include hepatomegaly and steatosis even in the absence of marked transaminase elevations).</p><p>&sect;&nbsp; <strong><em>Serum lipids and blood glucose</em></strong></p><p>Serum lipid and blood glucose levels may increase during antiretroviral therapy. Disease control and lifestyle changes may also be contributing factors. Consideration should be given to the measurement of serum lipids and blood glucose. Lipid disorders should be managed as clinically appropriate.</p><p>&sect;<strong>&nbsp; Immune Reconstitution Syndrome</strong></p><p>In HIV-infected patients with severe immune deficiency at the time of initiation of anti-retroviral therapy (ART), an inflammatory reaction to asymptomatic or residual opportunistic infections may arise and cause serious clinical conditions, or aggravation of symptoms. Typically, such reactions have been observed within the first few weeks or months of initiation of ART.&nbsp; Relevant examples are cytomegalovirus retinitis, generalised and/or focal mycobacterial infections and <em>Pneumocystis jiroveci </em>pneumonia (often referred to as PCP). Any inflammatory symptoms must be evaluated without delay and treatment initiated when necessary. Autoimmune disorders (such as Graves&rsquo; disease, polymyositis and Guillain-Barre syndrome) have also been reported to occur in the setting of immune reconstitution, however, the time to onset is more variable, and can occur many months after initiation of treatment and sometimes can be an atypical presentation.</p><p>&sect;&nbsp; <strong>Opportunistic infections</strong></p><p>Patients receiving <em>ZIAGEN</em> or any other antiretroviral therapy may still develop opportunistic infections and other complications of HIV infection. Therefore, patients should remain under close clinical observation by physicians experienced in the treatment of these associated HIV diseases.</p><p>&sect;&nbsp; <strong>Myocardial Infarction</strong></p><p>Several observational, epidemiological studies have reported an association with abacavir use and the risk of myocardial infarction.&nbsp; Meta-analyses of randomised controlled trials have observed no excess risk of myocardial infarction with abacavir use. To date, there is no established biological mechanism to explain a potential increase in risk. In totality the available data from observational studies and from controlled clinical trials show inconsistency and therefore the evidence for a causal relationship between abacavir treatment and the risk of myocardial infarction is inconclusive.</p><p>As a precaution the underlying risk of coronary heart disease should be considered when prescribing antiretroviral therapies, including abacavir, and action taken to minimize all modifiable risk factors (e.g. hypertension, hyperlipidaemia, diabetes mellitus and smoking).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The potential for drug interactions involving abacavir is low. In vitro studies have shown that abacavir has potential to inhibit cytochrome P450 1A1 (CYP1A1).<strong><em> </em></strong>Abacavir shows limited potential to inhibit metabolism mediated by the CYP3A4 enzyme. It has also been shown <em>in vitro</em> not to interact with drugs that are metabolised by CYP2C9 or CYP2D6 enzymes. Induction of hepatic metabolism has not been observed in clinical studies. Therefore, there is little potential for drug interactions with antiretroviral protease inhibitors and other drugs metabolised by major CYP<sub> </sub>enzymes. Clinical studies have shown that there are no clinically significant interactions between abacavir, zidovudine and lamivudine.</p><p><strong><em>Effect of Abacavir on the Pharmacokinetics of Other Agents</em></strong></p><p>In vitro, abacavir demonstrates no or weak inhibition of the drug transporters organic anion transporter 1B1 (OATP1B1), OATP1B3, breast cancer resistance protein (BCRP) or P-glycoprotein (Pgp) and minimal inhibition of organic cation transporter 1 (OCT1), OCT2 and multidrug and toxin extrusion protein 2-K (MATE2-K). Abacavir is therefore not expected to affect the plasma concentrations of drugs that are substrates of these drug transporters.</p><p>Abacavir is an inhibitor of MATE1 in vitro, however abacavir has low potential to affect the plasma concentrations of MATE1 substrates at therapeutic drug exposures (up to 600 mg).&nbsp;</p><p><strong><em>Effect of Other Agents on the Pharmacokinetics of Abacavir</em></strong><strong><em> </em></strong></p><p>In vitro, abacavir is not a substrate of OATP1B1, OATP1B3, OCT1, OCT2, OAT1, MATE1, MATE2-K, Multidrug resistance-associated protein 2 (MRP2) or MRP4,&nbsp; therefore drugs that modulate these transporters are not expected to affect abacavir plasma concentrations.</p><p>Although abacavir is a substrate of BCRP and Pgp in vitro, clinical studies demonstrate no clinically significant changes in abacavir pharmacokinetics when co-administered with lopinavir/ritonavir (Pgp and BCRP inhibitors).</p><p><strong><em>Interactions relevant to abacavir</em></strong></p><p><strong><em>Ethanol:</em> </strong>The metabolism of abacavir is altered by concomitant ethanol resulting in an increase in AUC of abacavir of about 41%. Given the safety profile of abacavir these findings are not considered clinically significant. Abacavir has no effect on the metabolism of ethanol.</p><p><strong><em>Methadone</em></strong><strong>:</strong> In a pharmacokinetic study, coadministration of 600 mg <em>ZIAGEN</em> twice daily with methadone showed a 35% reduction in abacavir C<sub>max</sub> and a 1 h delay in t<sub>max</sub>, but the AUC was unchanged. The changes in abacavir pharmacokinetics are not considered clinically relevant. In this study abacavir increased the mean methadone systemic clearance by 22 %. This change is not considered clinically relevant for the majority of patients, however, occasionally methadone re-titration may be required.</p><p><strong><em>Retinoids:</em></strong> Retinoid compounds such as isotretinoin, are eliminated via alcohol dehydrogenase. Interaction with abacavir is possible but has not been studied.</p><p><strong><em>Riociguat:</em></strong> In vitro, abacavir inhibits CYP1A1.&nbsp;Concomitant administration of a single dose of riociguat (0.5 mg) to HIV patients receiving the combination of abacavir/dolutegravir/lamivudine (600mg/50mg/300mg once daily) led to an approximately three-fold higher riociguat AUC<sub> (0-&infin;)</sub> when compared to historical riociguat AUC<sub> (0-&infin;)</sub> reported in healthy subjects. Riociguat dose may need to be reduced,&nbsp;consult the riociguat product labeling for dosing recommendations.<s> </s></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pregnancy</strong></p><p>Abacavir has been evaluated in the Antiretroviral Pregnancy Registry in over 2000 women during pregnancy and postpartum. Available human data from the Antiretroviral Pregnancy Registry do not show an increased risk of major birth defects for abacavir compared to the background rate <em>(see Clinical Studies)</em>. However, there are no adequate and well-controlled trials in pregnant women and the safe use of <em>ZIAGEN</em> in human pregnancy has not been established. Abacavir has been associated with findings in animal reproductive studies (<em>see Pre-clinical Safety Data</em>). Therefore, administration of <em>ZIAGEN</em> in pregnancy should be considered only if the benefit to the mother outweighs the possible risk to the foetus.</p><p>There have been reports of mild, transient elevations in serum lactate levels, which may be due to mitochondrial dysfunction, in neonates and infants exposed <em>in utero</em> or peri-partum to NRTIs. The clinical relevance of transient elevations in serum lactate is unknown. There have also been very rare reports of developmental delay, seizures and other neurological disease. However, a causal relationship between these events and NRTI exposure <em>in utero</em> or peri-partum has not been established. These findings do not affect current recommendations to use antiretroviral therapy in pregnant women to prevent vertical transmission of HIV</p><p><strong>Lactation</strong></p><p>Health experts recommend that where possible HIV infected women do not breast feed their infants in order to avoid transmission of HIV. <strong><em>&nbsp;</em></strong>In settings where formula feeding is not feasible, local official lactation and treatment guidelines should be followed when considering breast feeding during antiretroviral therapy<strong><em>.</em></strong></p><p>In a study after repeating oral administration of 300 mg abacavir twice daily (given as <em>TRIZIVIR</em>), the breast milk: maternal plasma ratio was 0.9. Most infants (8 out of 9) had non-detectable levels of abacavir (assay sensitivity 16ng/mL). Intracellular carbovir triphosphate (active metabolite of abacavir) levels in breastfed infants were not measured therefore the clinical relevance of the serum concentrations of the parent compound measured is unknown.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No currently available data suggest that <em>ZIAGEN</em> affects the ability to drive or operate machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>For many of the other adverse events reported, it is unclear whether they are related to <em>ZIAGEN</em>, to the wide range of medicinal products used in the management of HIV disease or as a result of the disease process.</p><p>&nbsp;</p><p>Many of those listed below (nausea, vomiting, diarrhea, fever, fatigue, rash) occur commonly as part of <em>ZIAGEN</em> hypersensitivity. Therefore, patients with any of these symptoms should be carefully evaluated for the presence of this hypersensitivity reaction. If <em>ZIAGEN</em> has been discontinued in patients due to experiencing any one of these symptoms and<strong> </strong>a decision is made to restart <em>ZIAGEN</em>, this should be done only under direct medical supervision (<em>see Warnings and Precautions - &ldquo;Special considerations following an interruption of ZIAGEN therapy&rdquo;</em>).</p><p>The majority of the adverse reactions listed below have not been treatment limiting. The following convention has been used for their classification: very common (more than 1/10), common (more than 1/100, less than 1/10), uncommon (more than 1/1,000, less than 1/100), rare (more than 1/10,000, less than 1/1,000) very rare (less than 1/10,000).</p><p>Clinical Trial Data</p><p>Metabolism and nutrition disorders&nbsp;</p><p>Common: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; anorexia.</p><p><strong>Nervous system disorders</strong></p><p>Common: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache.</p><p><strong>Gastrointestinal disorders</strong></p><p>Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nausea, vomiting, diarrhea.</p><p><strong>General disorders and administration site disorders</strong></p><p>Common: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fever, lethargy, fatigue.</p><p>In controlled clinical studies laboratory abnormalities related to <em>ZIAGEN</em> treatment were uncommon, with no differences in incidence observed between <em>ZIAGEN</em> treated patients and the control arms.</p><p>Paediatric population</p><p>The safety database to support abacavir once daily dosing in paediatric patients comes from the ARROW Trial (COL105677) in which 669 HIV-1 infected paediatric subjects received abacavir and lamivudine either once or twice daily (<em>see Clinical Studies</em>). No additional safety issues have been identified in paediatric subjects receiving either once or twice daily dosing compared to adults.</p><p>Post marketing Data</p><p>Metabolism and nutrition disorders&nbsp;</p><p>Common: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hyperlactataemia.</p><p>Rare: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; lactic acidosis (<em>see Warnings and Precautions)</em>.</p><p><strong>Gastrointestinal disorders</strong><em> </em></p><p>Rare: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pancreatitis has been reported, but a causal relationship to <em>ZIAGEN</em> treatment is uncertain.</p><p>Skin and subcutaneous tissue disorders</p><p>Common: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rash (without systemic symptoms).</p><p>Very rare: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis.</p><p>Description of Selected Adverse Reactions</p><p><em>Hypersensitivity (see also Warnings and Precautions):</em></p><p>Abacavir hypersensitivity reaction (HSR) has been identified as a common adverse reaction with abacavir therapy. The signs and symptoms of this hypersensitivity reaction are listed below. These have been identified either from clinical studies or post marketing surveillance. Those reported in <strong>at least 10% of patients</strong> with a hypersensitivity reaction are in bold text.</p><p>Almost all patients developing hypersensitivity reactions will have fever and/or rash (usually maculopapular or urticarial) as part of the syndrome, however, reactions have occurred without rash or fever. Other key symptoms include gastrointestinal, respiratory or constitutional symptoms such as lethargy and malaise.</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Skin:</p></td><td style="vertical-align:top"><p>&nbsp;<strong>Rash</strong> (usually maculopapular or urticarial)</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal tract:</p></td><td style="vertical-align:top"><p>&nbsp;<strong>Nausea, vomiting, diarrhoea, abdominal pain,</strong> mouth ulceration</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory tract:</p></td><td style="vertical-align:top"><p>&nbsp;<strong>Dyspnoea, cough,</strong> sore throat, adult respiratory distress syndrome, respiratory failure</p></td></tr><tr><td style="vertical-align:top"><p>Miscellaneous:</p></td><td style="vertical-align:top"><p>&nbsp;<strong>Fever, fatigue, malaise</strong>, oedema, lymphadenopathy, hypotension, conjunctivitis, anaphylaxis</p></td></tr><tr><td style="vertical-align:top"><p>Neurological/Psychiatry:</p></td><td style="vertical-align:top"><p>&nbsp;<strong>Headache,</strong> paraesthesia</p></td></tr><tr><td style="vertical-align:top"><p>Haematological:</p></td><td style="vertical-align:top"><p>&nbsp;Lymphopenia</p></td></tr><tr><td style="vertical-align:top"><p>Liver/pancreas:</p></td><td style="vertical-align:top"><p>&nbsp;<strong>Elevated liver function tests,</strong> hepatic failure</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal:</p></td><td style="vertical-align:top"><p><strong>&nbsp;Myalgia</strong>, rarely myolysis, arthralgia, elevated creatine phosphokinase</p></td></tr><tr><td style="vertical-align:top"><p>Urology:</p></td><td style="vertical-align:top"><p>&nbsp;Elevated creatinine, renal failure</p></td></tr></tbody></table><p>&nbsp;</p><p>Restarting abacavir following an abacavir HSR results in a prompt return of symptoms within hours. This recurrence of the HSR is usually more severe than on initial<strong> </strong>presentation, and may include life-threatening hypotension and death. Reactions have also occurred infrequently after restarting abacavir in patients who had only one of the key symptoms of hypersensitivity (see above) prior to stopping abacavir; and on very rare occasions have also been seen in patients who have restarted therapy with no preceding symptoms of a HSR (i.e., patients previously considered to be abacavir tolerant).</p><p>For details of clinical management in the event of a suspected abacavir HSR see Warnings and Precautions.</p><p>&nbsp;</p><p><strong>To report any side effect(s):</strong></p><p><strong><em>Kingdom of Saudi Arabia</em></strong></p><p><strong>-National Pharmacovigilance centre (NPC)</strong></p><ul><li>Reporting hotline: 19999</li><li>E-mail : &nbsp;npc.drug@sfda.gov.sa</li></ul><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa</p><p><strong>-GSK - Head Office, Jeddah</strong></p><ul><li>Tel:&nbsp; +966-12-6536666</li><li>Mobile: +966-56-904-9882</li><li>Email: saudi.safety@gsk.com<u> </u></li><li>Website: https://gskpro.com/en-sa/<u> </u></li></ul><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; P.O. Box 55850, Jeddah 21544, Saudi Arabia</p><p><strong>For any information about this medicinal product, please contact:</strong></p><p><strong>GSK- Head Office, Jeddah</strong></p><ul><li>Tel:&nbsp; +966-12-6536666</li><li>Mobile: +966-56-904-9882</li><li>Email: gcc.medinfo@gsk.com</li><li>Website: https://gskpro.com/en-sa/<u> </u></li><li>P.O. Box 55850, Jeddah 21544, Saudi Arabia</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Single doses up to 1200 mg and daily doses up to 1800 mg of abacavir have been administered to patients in clinical studies. No unexpected adverse reactions were reported. The effects of higher doses are not known.</p><p>If overdosage occurs the patient should be monitored for evidence of toxicity (<em>see Adverse Reactions</em>), and standard supportive treatment applied as necessary. It is not known whether abacavir can be removed by peritoneal dialysis or haemodialysis.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group - nucleoside analogue, <strong>ATC Code:</strong> J05A F06.</p><p><strong>Mechanism of action</strong></p><p>Abacavir is a nucleoside analogue reverse transcriptase inhibitor. It is a potent selective inhibitor of HIV-1 and HIV-2, including HIV-1 isolates with reduced susceptibility to zidovudine, lamivudine, zalcitabine, didanosine or nevirapine. Abacavir is metabolised intracellularly to the active moiety, carbovir 5&rsquo;-triphosphate (TP). <em>In vitro</em> studies have demonstrated that its mechanism of action in relation to HIV is inhibition of the HIV reverse transcriptase enzyme, an event which results in chain termination and interruption of the viral replication cycle. The antiviral activity of abacavir in cell culture was not antagonized when combined with the nucleoside reverse transcriptase inhibitors (NRTIs) didanosine, emtricitabine, lamivudine, stavudine, tenofovir, zalcitabine or zidovudine, the non-nucleoside reverse transcriptase inhibitor (NNRTI) nevirapine, or the protease inhibitor (PI) amprenavir.</p><p><strong>Pharmacodynamic effects</strong></p><p>In a study of 20 HIV-infected patients receiving <em>ZIAGEN</em> 300&nbsp;mg twice daily, with only one 300&nbsp;mg dose taken prior to the 24 hours sampling period, the geometric mean terminal carbovir-TP intracellular half-life at steady-state was 20.6 hours, compared to the geometric mean abacavir plasma half-life in this study of 2.6 hours.&nbsp; The steady state pharmacokinetic properties of <em>ZIAGEN</em> 600&nbsp;mg once daily was compared to <em>ZIAGEN</em> 300&nbsp;mg twice daily in a crossover study in 27 HIV-infected patients. Intracellular carbovir triphosphate exposures in peripheral blood mononuclear cells were higher for <em>ZIAGEN</em> 600&nbsp;mg once daily with respect to AUC24,ss(32 %, higher), Cmax 24,ss (99% higher) and trough values (18% higher), compared to the 300 mg twice daily regimen.&nbsp; These data support the use of <em>ZIAGEN</em> 600&nbsp;mg once daily for the treatment of HIV infected patients. Additionally, the efficacy and safety of <em>ZIAGEN</em> given once daily has been demonstrated in a pivotal clinical study (CNA30021- <em>see Clinical Studies</em>).</p><p>Abacavir-resistant isolates of HIV-1 have been selected <em>in vitro</em> and are associated with specific genotypic changes in the reverse transcriptase (RT) codon region (codons M184V, K65R, L74V and Y115F). Viral resistance to abacavir develops relatively slowly <em>in vitro</em> and <em>in vivo</em>, requiring multiple mutations to reach an eight-fold increase in IC<sub>50</sub> over wild-type virus, which may be a clinically relevant level.</p><p>Isolates resistant to abacavir may also show reduced sensitivity to lamivudine, zalcitabine and/or didanosine, but remain sensitive to zidovudine and stavudine. Cross resistance between abacavir and protease inhibitors or non nucleoside reverse transcriptase inhibitors is unlikely. Treatment failure following initial therapy with abacavir, lamivudine and zidovudine is mainly associated with the M184V alone, thus maintaining many therapeutic options for a second line regimen.</p><p>Abacavir penetrates the cerebrospinal fluid (CSF) (<em>see Pharmacokinetics</em>), and has been shown to reduce HIV-1 RNA levels in the CSF. In combination with other antiretrovirals it may have a role in the prevention of HIV related neurological complications, and may delay the development of resistance in this sanctuary site.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><em>Absorption</em></strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><i style='mso-bidi-font-style:normal'><span
style='mso-bidi-font-size:10.0pt;font-family:"Times New Roman",serif;
mso-ascii-theme-font:major-bidi;mso-fareast-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi;color:black;
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB'><span style='mso-element:
field-begin'></span> DOCVARIABLE vault_nd_e2cbe008-55e1-483a-b0c1-d74c05f9ed52
\* MERGEFORMAT <span style='mso-element:field-separator'></span></span></i></b><![endif]--><strong><em>&nbsp;</em></strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><i style='mso-bidi-font-style:normal'><span
style='mso-bidi-font-size:10.0pt;font-family:"Times New Roman",serif;
mso-ascii-theme-font:major-bidi;mso-fareast-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi;color:black;
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB'><span style='mso-element:
field-end'></span></span></i></b><![endif]--></p><p>Abacavir is rapidly and well absorbed following oral administration. The absolute bioavailability of oral abacavir in adults is about 83%.&nbsp; Following oral administration, the mean time (t<sub>max</sub>) to maximal serum concentrations of abacavir is about 1.5 hours for the tablet formulation and about 1 hour for the solution formulation.</p><p>There are no differences observed between the AUC for the tablet or solution. At a dosage of 300&nbsp;mg twice daily, the mean steady state C<sub>max</sub> of abacavir from tablet administration was 3.00 micrograms/ml, and the mean AUC over a dosing interval of 12&nbsp;h was 6.02 micrograms.h/ml (daily AUC of approximately 12.0 micrograms.h/ml). The C<sub>max</sub> value for the oral solution is slightly higher than the tablet.&nbsp; After a 600&nbsp;mg <em>ZIAGEN</em> tablet dose, the mean abacavir C<sub>max</sub> was approximately 4.26 micrograms/ml and the mean AUC<sub>&yen;</sub> was 11.95 micrograms.h/ml.</p><p>Food delayed absorption and decreased C<sub>max</sub> but did not affect overall plasma concentrations (AUC). Therefore, <em>ZIAGEN</em> can be taken with or without food.</p><p>Administration of crushed tablets with a small amount of semi-solid food or liquid would not be expected to have an impact on the pharmaceutical quality, and would therefore not be expected to alter the clinical effect. This conclusion is based on the physiochemical and pharmacokinetic characteristics of the active ingredient and the in vitro dissolution behaviour of abacavir tablets in water, assuming that the patient crushes and transfers 100% of the tablet and ingests immediately.</p><p><strong><em>Distribution</em></strong></p><p>Following I.V. administration, the apparent volume of distribution was about 0.8&nbsp;l/kg, indicating that abacavir<em> </em>penetrates freely into body tissues.</p><p>Studies in HIV infected patients have shown good penetration of abacavir into the cerebrospinal fluid (CSF), with a CSF to plasma AUC ratio of between 30 to 44%. In a Phase I pharmacokinetic study, the penetration of abacavir into the CSF was investigated following administration of <em>ZIAGEN</em> 300&nbsp;mg twice a day. The mean concentration of abacavir achieved in the CSF 1.5 hours post dose was 0.14&nbsp;micrograms/ml. In a further pharmacokinetic study of 600&nbsp;mg twice a day, the CSF concentration of abacavir increased over time, from approximately 0.13&nbsp;micrograms/ml at 0.5 to 1 hour after dosing, to approximately 0.74&nbsp;micrograms/ml after 3 to 4 hours. While peak concentrations may not have been attained by 4 hours, the observed values are 9-fold greater than the IC50 of abacavir of 0.08&nbsp;micrograms/ml or 0.26 micromoles.</p><p>Plasma protein binding studies <em>in vitro</em> indicate that abacavir binds only low to moderately (circa 49%) to human plasma proteins at therapeutic concentrations. This indicates a low likelihood for drug interactions through plasma protein binding displacement.</p><p><strong><em>Metabolism</em></strong></p><p>Abacavir is primarily metabolised by the liver with less than 2% of the administered dose being renally excreted, as unchanged compound. The primary pathways of metabolism in man are by alcohol dehydrogenase and by glucuronidation to produce the 5&#39;-carboxylic acid and 5&#39;-glucuronide which account for about 66% of the administered dose. These metabolites are excreted in the urine.</p><p><strong><em>Elimination</em></strong></p><p>The mean half-life of abacavir is about 1.5 hours. Following multiple oral doses of <em>ZIAGEN</em> 300&nbsp;mg twice a day there is no significant drug accumulation. Elimination of abacavir is via hepatic metabolism with subsequent excretion of metabolites primarily in the urine. The metabolites and unchanged abacavir account for about 83% of the administered <em>ZIAGEN</em> dose in the urine the remainder is eliminated in the faeces.</p><p><strong><em>Special Patient Populations </em></strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Children</strong></p><p>Abacavir is rapidly and well absorbed from oral solution and tablet formulations administered to children. Plasma abacavir exposure has been shown to be the same for both formulations when administered at the same dose. Children receiving abacavir oral solution according to the recommended dosage regimen achieve plasma abacavir exposure similar to adults.&nbsp; Children receiving abacavir oral tablets according to the recommended dosage regimen achieve higher plasma abacavir exposure than children receiving oral solution because higher mg/kg doses are administered with the tablet formulation (<em>see Dosage and Administration</em>). Paediatric pharmacokinetic studies have demonstrated that once daily dosing provides equivalent AUC<strong><em><sub>0-24</sub></em></strong> to twice daily dosing of the same total daily dose for both oral solution and tablet formulations.</p><p>There are insufficient safety data to recommend the use of <em>ZIAGEN</em> in infants less than 3&nbsp;months old. The limited data available indicate that a dose of 2&nbsp;mg/kg in neonates less than 30 days old provides similar or greater AUCs, compared to the 8&nbsp;mg/kg dose administered to older children.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Elderly</strong></p><p>The pharmacokinetics of abacavir have not been studied in patients over 65 years of age. When treating elderly patients consideration needs to be given to the greater frequency of decreased hepatic, renal and cardiac function, and concomitant disease or another drug therapy.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Renally impaired</strong></p><p>Abacavir is primarily metabolised by the liver with approximately 2% of abacavir excreted unchanged in the urine. The pharmacokinetics of abacavir in patients with end-stage renal disease is similar to patients with normal renal function. Therefore, no dosage reduction is required in patients with renal impairment.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Hepatically impaired</strong></p><p>Abacavir is metabolised primarily by the liver. The pharmacokinetics of abacavir have been studied in patients with mild hepatic impairment (Child-Pugh score 5 to 6). The results showed that there was a mean increase of 1.89-fold in the abacavir AUC, and 1.58-fold in the half-life of abacavir. The AUCs of the metabolites were not modified by the liver disease. However, the rates of formation and elimination of these were decreased.</p><p>In order to achieve exposures that are within the therapeutic range of patients without liver disease, patients with mild hepatic impairment should receive 200&nbsp;mg <em>ZIAGEN</em> twice daily. The pharmacokinetics have not been studied in patients with moderate or severe hepatic impairment, therefore <em>ZIAGEN</em> is not recommended in these patient groups.</p><p><strong>Clinical Studies</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:13.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman",serif;mso-ascii-theme-font:major-bidi;
mso-fareast-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-theme-font:major-bidi;mso-ansi-language:EN-GB;mso-fareast-language:
EN-GB'><span style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_d24f4e9a-d0cb-4f85-9e13-050a8a1cca87 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:13.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman",serif;mso-ascii-theme-font:major-bidi;
mso-fareast-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-theme-font:major-bidi;mso-ansi-language:EN-GB;mso-fareast-language:
EN-GB'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p>In a double-blind clinical study over 48 weeks in treatment na&iuml;ve adult patients, the combination of abacavir, lamivudine and zidovudine showed an equivalent antiviral effect to the combination with indinavir, lamivudine and zidovudine in the primary analysis of efficacy.&nbsp; In a secondary analysis of patients with baseline plasma HIV-1 RNA levels above 100,000 copies per ml, patients receiving the combination containing indinavir had a superior response. Patients with baseline plasma HIV-1 RNA below 100,000 copies per ml had an equivalent response to both treatments.</p><p>A once daily regimen of abacavir and lamivudine was investigated in a multicentre, double-blind, controlled study (CNA30021) of 770&nbsp;HIV-infected, therapy-na&iuml;ve adults. They were randomised to receive either <em>ZIAGEN</em> 600&nbsp;mg once daily or 300&nbsp;mg twice daily, both in combination with lamivudine 300&nbsp;mg once daily and efavirenz 600&nbsp;mg once daily. Patients were stratified at baseline based on plasma HIV-1 RNA less than or equal to100,000 copies/ml or greater than 100,000 copies/ml. The duration of double-blind treatment was at least 48&nbsp;weeks. The results are summarised in the table below.</p><p><strong>Virological Response Based on Plasma HIV-1 RNA less than 50 copies/ml</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:12.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman",serif;mso-ascii-theme-font:major-bidi;
mso-fareast-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-theme-font:major-bidi;mso-ansi-language:EN-GB;mso-fareast-language:
EN-GB'><span style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_b16e0280-2a3c-40f1-9f06-97ab6bd18961 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:12.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman",serif;mso-ascii-theme-font:major-bidi;
mso-fareast-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-theme-font:major-bidi;mso-ansi-language:EN-GB;mso-fareast-language:
EN-GB'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p><strong>at Week 48 ITT-Exposed Population</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>Populations</p></td><td><p>ABC once/day<br />+ 3TC + EFV<br />(N = 384 )</p></td><td><p>ABC twice/day<br />&nbsp;+ 3TC + EFV<br />(N = 386 )</p></td></tr><tr><td style="vertical-align:top"><p>Sub-group by baseline RNA</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Less than or equal to 100,000 copies/ml</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>141/217 (65%)</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>145/217 (67%)</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Greater than 100,000 copies/ml</p></td><td style="vertical-align:top"><p>112/167 (67%)</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>116/169 (69%)</p></td></tr><tr><td style="vertical-align:top"><p>Total population</p></td><td style="vertical-align:top"><p>253/384 (66%)</p></td><td style="vertical-align:top"><p>261/386 (68%)</p></td></tr></tbody></table><p>The abacavir once daily group was demonstrated to be non-inferior when compared to the twice daily group in the overall and base-line viral load sub-groups. The incidence of adverse events reported was<strong><em> </em></strong>similar in the two treatment groups.</p><p>Genotypic analysis was attempted for all subjects with virologic failure (confirmed HIV RNA greater than 50 copies/ml). There was a low overall incidence of virologic failure in both the once and twice daily treatment groups (10% and 8%, respectively). Additionally, genotyping was restricted to samples with plasma HIV-1 RNA greater than 500 copies/ml. These factors resulted in a small sample size.&nbsp; Therefore, no firm conclusions could be drawn regarding differences in treatment emergent mutations between the two treatment groups.&nbsp; Reverse transcriptase amino acid residue 184 was consistently the most frequent position for NRTI resistance-associated mutations (M184V or M184I). The second most frequent mutation was L74V. Mutations Y115F and K65R were uncommon.</p><p>A randomised comparison of a regimen including once daily vs twice daily dosing of abacavir and lamivudine was undertaken within a randomised, multicentre, controlled study of HIV-infected, paediatric patients. 1206 paediatric patients aged 3 months to 17 years enrolled in the ARROW Trial (COL105677) and were dosed according to the weight - band dosing recommendations in the World Health Organisation treatment guidelines (Antiretroviral therapy of HIV infection in infants and children, 2006). After 36 weeks on a regimen including twice daily abacavir and lamivudine, 669 eligible subjects were randomised to either continue twice daily dosing or switch to once daily abacavir and lamivudine for at least 96 weeks.&nbsp; The results are summarised in the table below:</p><p><strong>Virological Response Based on Plasma HIV-1 RNA less than 80 copies/ml at Week 48 and Week 96 in the Once Daily versus Twice Daily abacavir + lamivudine randomisation of ARROW (Observed Analysis)</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:456px"><tbody><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Twice Daily</strong></p><p><strong>n/N (%)</strong></p></td><td style="vertical-align:top"><p><strong>Once Daily</strong></p><p><strong>n/N (%)</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Week 0 (After &ge;36 Weeks on Treatment)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Plasma HIV-1 RNA &lt;80 c/mL</p></td><td style="vertical-align:top"><p>250/331 (76)</p></td><td style="vertical-align:top"><p>237/335 (71)</p></td></tr><tr><td style="vertical-align:top"><p>Risk difference (once daily-twice daily)</p></td><td colspan="2" style="vertical-align:top"><p>-4.8% (95% CI -11.5% to +1.9%), p=0.16</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Week 48</strong></p></td></tr><tr><td style="vertical-align:top"><p>Plasma HIV-1 RNA &lt;80 c/mL</p></td><td style="vertical-align:top"><p>242/331 (73)</p></td><td style="vertical-align:top"><p>236/330 (72)</p></td></tr><tr><td style="vertical-align:top"><p>Risk difference (once daily-twice daily)</p></td><td colspan="2" style="vertical-align:top"><p>-1.6% (95% CI -8.4% to +5.2%), p=0.65</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Week 96</strong></p></td></tr><tr><td style="vertical-align:top"><p>Plasma HIV-1 RNA &lt;80 c/mL</p></td><td style="vertical-align:top"><p>234/326 (72)</p></td><td style="vertical-align:top"><p>230/331 (69)</p></td></tr><tr><td style="vertical-align:top"><p>Risk difference (once daily-twice daily)</p></td><td colspan="2" style="vertical-align:top"><p>-2.3% (95% CI -9.3% to +4.7%), p=0.52</p></td></tr></tbody></table><p>The abacavir/lamivudine once daily dosing group was demonstrated to be non-inferior to the twice daily group according to the pre-specified non-inferiority margin of -12%, for the primary endpoint of &lt;80 c/mL at Week 48 as well as at Week 96 (secondary endpoint) and all other thresholds tested (&lt;200c/mL, &lt;400c/mL, &lt;1000c/mL), which all fell well within this non-inferiority margin. Subgroup analyses testing for heterogeneity of once vs twice daily demonstrated no significant effect of sex, age, or viral load at randomisation. Conclusions supported non-inferiority regardless of analysis method.</p><p>In a study comparing&nbsp; unblinded NRTI combinations (with or without blinded nelfinavir) in children, a significantly greater proportion treated with abacavir and lamivudine (73%) or abacavir and zidovudine (70%) had HIV-1 RNA less than or equal to 400 copies/ml at 24 weeks, compared with those treated with lamivudine and zidovudine (44%).&nbsp; In children with extensive antiretroviral exposure, a modest but sustained effect of the combination of abacavir, lamivudine and zidovudine was observed.</p><p>In therapy experienced patients, the degree of benefit from<strong><em> </em></strong>the addition of abacavir will depend on the nature and duration of prior therapy which may have selected for cross resistance to abacavir.</p><p><strong><em>Antiretroviral Pregnancy Registry</em></strong><!--[if supportFields]><b style='mso-bidi-font-weight:
normal'><i><span style='font-size:12.0pt;mso-bidi-font-size:10.0pt;font-family:
"Times New Roman",serif;mso-ascii-theme-font:major-bidi;mso-fareast-font-family:
"Times New Roman";mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi;
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB'><span style='mso-element:
field-begin'></span> DOCVARIABLE vault_nd_01659b72-abda-4b23-adc6-14c422c43c21
\* MERGEFORMAT <span style='mso-element:field-separator'></span></span></i></b><![endif]--><strong><em>&nbsp;</em></strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><i><span style='font-size:12.0pt;
mso-bidi-font-size:10.0pt;font-family:"Times New Roman",serif;mso-ascii-theme-font:
major-bidi;mso-fareast-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-theme-font:major-bidi;mso-ansi-language:EN-GB;mso-fareast-language:
EN-GB'><span style='mso-element:field-end'></span></span></i></b><![endif]--></p><p>The Antiretroviral Pregnancy Registry has received prospective reports of over 2,000 exposures to abacavir during pregnancy resulting in live birth. These consist of over 800 exposures during the first trimester, over 1,100 exposures during the second/third trimester and included 27 and 32 birth defects respectively. The prevalence (95% CI) of defects in the first trimester was 3.1% (2.0, 4.4%) and in the second/third trimester, 2.7% (1.9, 3.9%). Among pregnant women in the reference population, the background rate of birth defects is 2.7%. There was no association between abacavir, and overall birth defects observed in the Antiretroviral Pregnancy Registry.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Carcinogenesis, mutagenesis</p><p>Abacavir was not mutagenic in bacterial tests but showed activity <em>in vitro</em> in the human lymphocyte chromosome aberration assay, the mouse lymphoma assay, and the <em>in vivo</em> micronucleus test. This is consistent with the known activity of other nucleoside analogues. These results indicate that abacavir is a weak clastogen both <em>in vitro</em> and <em>in vivo</em> at high test concentrations.</p><p>Carcinogenicity studies with orally administered abacavir in mice and rats showed an increase in the incidence of malignant and non-malignant tumours. Malignant tumours occurred in the preputial gland of males and the clitoral gland of females of both species, and in the liver, urinary bladder, lymph nodes and the subcutis of female rats.</p><p>The majority of these tumours occurred at the highest abacavir dose of 330&nbsp;mg/kg/day in mice and 600&nbsp;mg/kg/day in rats. These dose levels were equivalent to 24 to 32 times the expected systemic exposure in humans. The exception was the preputial gland tumour which occurred at a dose of 110&nbsp;mg/kg. This is equivalent to six times the expected human systemic exposure. There is no structural counterpart for this gland in humans. While the carcinogenic potential in humans is unknown, these data suggest that a carcinogenic risk to humans is outweighed by the potential clinical benefit.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Reproductive toxicology</p><p>Placental transfer of abacavir and/or its related metabolites has been shown to occur in animals. Evidence of toxicity to the developing embryo and foetuses occurred only in rats at maternally toxic doses of 500&nbsp;mg/kg/day and above. This dose is equivalent to 32 to 35 times human therapeutic exposure based on AUC. The findings included foetal oedema, variations and malformations, resorptions, decreased foetal body weight and an increase in still births. The dose at which there were no effects on pre or post natal development was 160&nbsp;mg/kg/day. This dose is equivalent to an exposure of about 10 times that in humans. Similar findings were not observed in rabbits.</p><p>A fertility study in the rat has shown that doses up to 500&nbsp;mg/kg of abacavir had no effect on male or female fertility.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Animal toxicology and/or pharmacology </strong></p><p>Mild myocardial degeneration in the heart of mice and rats was observed following administration of abacavir for two years. The systemic exposures were equivalent to 7 to 24 times the expected systemic exposure in humans. The clinical relevance of this finding has not been determined.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Tablet Core</strong></p><p>Microcrystalline cellulose</p><p>Sodium starch glycollate</p><p>Magnesium stearate</p><p>Colloidal anhydrous silica.</p><p><strong>Tablet Coating</strong></p><p>Triacetin</p><p>Methylhydroxypropylcellulose</p><p>Titanium dioxide</p><p>Polysorbate 80</p><p>Iron oxide yellow.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>None known.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                The expiry date is indicated on the packaging.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>ZIAGEN</em> tablets are available in polyvinyl chloride/foil or polyvinyl chloride/child resistant foil blister packs containing 60 tablets.</p><p>&nbsp;</p><p>&nbsp;</p><p>Not all presentations are available in every country.</p><p><em>ZIAGEN</em> is trademark owned by or licensed to the ViiV Healthcare group of companies.</p><p>&copy;2023 ViiV Healthcare group of companies. All rights reserved</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="1" align="center" cellspacing="1" cellpadding="1" style="width:800px"><tbody><tr><td><p style="text-align:center"><strong>Alert Card</strong><!--[if supportFields]><b style='mso-bidi-font-weight:normal'><span
lang=EN-US style='font-size:14.0pt;mso-bidi-font-size:11.0pt;line-height:107%;
font-family:"Times New Roman",serif;mso-ascii-theme-font:major-bidi;mso-hansi-theme-font:
major-bidi;mso-bidi-theme-font:major-bidi;color:black'><span style='mso-element:
field-begin'></span> DOCVARIABLE vault_nd_3cd825cd-494c-4e1b-a339-066ba9c18362
\* MERGEFORMAT <span style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span lang=EN-US style='font-size:14.0pt;
mso-bidi-font-size:11.0pt;line-height:107%;font-family:"Times New Roman",serif;
mso-ascii-theme-font:major-bidi;mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:
major-bidi;color:black'><span style='mso-element:field-end'></span></span></b><![endif]--></p><table border="1" align="center" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td><p style="text-align:center"><strong>IMPORTANT ALERT CARD</strong></p><p style="text-align:center"><strong><em>ZIAGEN<sup>&nbsp; </sup></em></strong><strong>(abacavir sulfate) tablets or oral solution </strong></p><p style="text-align:center"><strong>Carry this card with you at all times</strong></p></td></tr></tbody></table><p>Patients taking <em>ZIAGEN</em> may develop a hypersensitivity reaction (serious allergic reaction)<strong> </strong>which <strong>can be life threatening </strong>if treatment with <em>ZIAGEN</em> is continued. <strong>CONTACT&nbsp; YOUR DOCTOR IMMEDIATELY for advice on whether you should stop taking <em>ZIAGEN</em> if</strong>:</p><p><strong>1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you get a skin rash OR</strong></p><p><strong>2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you get one or more symptoms from at least TWO of the following groups</strong></p><p><strong>-&nbsp; </strong>fever</p><p><strong>-&nbsp; </strong>shortness of breath, sore throat or cough</p><p><strong>-&nbsp; </strong>nausea or vomiting or diarrhoea or abdominal pain</p><p><strong>-&nbsp; </strong>severe tiredness or achiness or generally ill feeling</p><p>If you have discontinued <em>ZIAGEN </em>due to this reaction, <strong>YOU MUST NEVER</strong> take <em>ZIAGEN</em> or any other medicine containing abacavir (<em>KIVEXA</em>, <em>TRIZIVIR, </em>or<em> TRIUMEQ</em>) again, as <strong>within hours</strong> you may experience a life-threatening lowering of your blood pressure or death.</p><p><strong>CARTON PANEL</strong><!--[if supportFields]><b style='mso-bidi-font-weight:normal'><span
lang=EN-US style='font-size:12.0pt;mso-bidi-font-size:11.0pt;line-height:107%;
font-family:"Times New Roman",serif;mso-ascii-theme-font:major-bidi;mso-hansi-theme-font:
major-bidi;mso-bidi-theme-font:major-bidi;color:black'><span style='mso-element:
field-begin'></span> DOCVARIABLE VAULT_ND_ad423727-e1df-4ee0-b6e8-3b39e2c2da81
\* MERGEFORMAT <span style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span lang=EN-US style='font-size:12.0pt;
mso-bidi-font-size:11.0pt;line-height:107%;font-family:"Times New Roman",serif;
mso-ascii-theme-font:major-bidi;mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:
major-bidi;color:black'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p>The following text must be included on one of the carton panels:</p><p style="margin-left:40px"><strong>Detach enclosed Alert Card, it contains important safety information.</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span lang=EN-US style='font-size:12.0pt;
mso-bidi-font-size:11.0pt;line-height:107%;font-family:"Times New Roman",serif;
mso-ascii-theme-font:major-bidi;mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:
major-bidi;color:black;layout-grid-mode:line'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_3fd57002-ac15-4c42-a09c-78cc309f31ce \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span lang=EN-US style='font-size:12.0pt;
mso-bidi-font-size:11.0pt;line-height:107%;font-family:"Times New Roman",serif;
mso-ascii-theme-font:major-bidi;mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:
major-bidi;color:black;layout-grid-mode:line'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p style="margin-left:40px">WARNING! In case of any symptoms suggesting hypersensitivity reactions, contact your doctor IMMEDIATELY.</p><p style="margin-left:40px">&ldquo;<strong>Pull here</strong>&rdquo; (with Alert card attached).</p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Manufactured by: 
Delpharm Poznań Spółka Akcyjna, ul. Grunwaldzka 189, 60-322 Poznan, Poland

Marketing Authorisation Holder: 
Glaxo Saudi Arabia Ltd.* Jeddah, KSA.
Address: P.O. Box 22617 Jeddah 21416 – Kingdom of Saudi Arabia.
*member of the GlaxoSmithKline group of companies 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Version number: GDS33 /IPI14
Date of issue: 20 June 2022
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>